US20050215991A1 - Cardiac drug delivery system and method of use - Google Patents

Cardiac drug delivery system and method of use Download PDF

Info

Publication number
US20050215991A1
US20050215991A1 US11/110,143 US11014305A US2005215991A1 US 20050215991 A1 US20050215991 A1 US 20050215991A1 US 11014305 A US11014305 A US 11014305A US 2005215991 A1 US2005215991 A1 US 2005215991A1
Authority
US
United States
Prior art keywords
tissue
fluid
structure
carrier
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/110,143
Inventor
Peter Altman
John Altman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioCardia Inc
Original Assignee
BioCardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/816,850 priority Critical patent/US6086582A/en
Priority to US09/260,641 priority patent/US6358247B1/en
Priority to US10/101,301 priority patent/US7104988B2/en
Application filed by BioCardia Inc filed Critical BioCardia Inc
Priority to US11/110,143 priority patent/US20050215991A1/en
Publication of US20050215991A1 publication Critical patent/US20050215991A1/en
Assigned to BIOCARDIA, INC. reassignment BIOCARDIA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALTMAN, JOHN D., ALTMAN, PETER A.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1492Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • A61N1/057Anchoring means; Means for fixing the head inside the heart
    • A61N1/0573Anchoring means; Means for fixing the head inside the heart chacterised by means penetrating the heart tissue, e.g. helix needle or hook
    • A61N1/0575Anchoring means; Means for fixing the head inside the heart chacterised by means penetrating the heart tissue, e.g. helix needle or hook with drug delivery
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238Type of minimally invasive operation
    • A61B2017/00243Type of minimally invasive operation cardiac
    • A61B2017/00247Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00005Cooling or heating of the probe or tissue immediately surrounding the probe
    • A61B2018/00011Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00273Anchoring means for temporary attachment of a device to tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00351Heart
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345Vascular system
    • A61B2018/00351Heart
    • A61B2018/00392Transmyocardial revascularisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577Ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00839Bioelectrical parameters, e.g. ECG, EEG
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B2018/1405Electrodes having a specific shape
    • A61B2018/1425Needle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B2018/1405Electrodes having a specific shape
    • A61B2018/1435Spiral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2218/00Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2218/001Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
    • A61B2218/002Irrigation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082Catheter tip comprising a tool
    • A61M25/0084Catheter tip comprising a tool being one or more injection needles
    • A61M2025/0089Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082Catheter tip comprising a tool
    • A61M25/0084Catheter tip comprising a tool being one or more injection needles

Abstract

A system is disclosed, for administering a therapeutic agent locally and to a depth within cardiac tissue. An elongate, flexible catheter contains a flexible electric conductor and supports at its distal end an implantable electrode incorporating a penetrating element, typically a fixation helix or a linear needle that penetrates cardiac tissue as the electrode is implanted. A therapeutic agent is delivered through the electrode, to the cardiac tissue surrounding the penetrating element. The electrode can act as a sensor to monitor an electrical condition of the surrounding cardiac tissue and to control delivery of the agent responsive to the sensed electrical condition. Several embodiments feature a distal reservoir adjacent the electrode, for effecting transient deliveries of the therapeutic agent in minute quantities. Other embodiments are disclosed for providing sustained deliveries of agents.

Description

  • This is a divisional of copending prior application Ser. No. 10/101,301, filed Mar. 19, 2002 as a divisional of application Ser. No. 09/260,641 (now U.S. Pat. No. 6,358,247), filed Mar. 2, 1999 as a divisional of application Ser. No. 08/816,850 (now U.S. Pat. No. 6,086,582), filed Mar. 13, 1997.
  • FIELD OF THE INVENTION
  • This invention relates to site specific delivery of therapeutic agents, structures and catheter systems to achieve site specific delivery of therapeutic agents, and means for implanting and using these systems to enable delivery of therapeutic agents to the body. More specifically, this invention relates to delivery of pharmacological agents to specific regions of the heart at a depth within the heart wall.
  • BACKGROUND OF THE INVENTION
  • It is possible to identify particular sites within the myocardium which may benefit from local drug release therapy. Examples of problematic tissue which may benefit form local drug release therapy are ischemic sites and arrhythmogenic sites. Different means and methods for delivering agents to these sites will be disclosed in detail.
  • Ischemic Sites
  • Ischemic tissue is characterized by limited metabolic processes which cause poor functionality. The tissue lacks oxygen, nutrients, and means for disposing of wastes. This hinders the normal functioning of the heart cells or myocytes in an ischemic region. If an ischemic, or damaged, region of the heart does not receive enough nutrients to sustain the myocytes they are said to die, and the tissue is said to become infarcted. Ischemia is reversible, such that cells may return to normal function once they receive the proper nutrients. Infarction is irreversible.
  • Non-invasive systemic delivery of anti-ischemic agents such as nitrates or vasodilators allows the heart to work less by reducing vascular resistance. Some vascular obstructions are treated by the systemic delivery of pharmacological agents such as TPA, urokinase, or antithrombolytics which can break up the obstruction. Catheter based techniques to remove the vascular obstructions such as percutaneous transluminal coronary angioplasty (PTCA), atherectomy devices, and stents can increase myocardial perfusion. More drastic, but very reliable procedures such as coronary artery bypass surgery can also be performed. All of these techniques treat the root cause of poor perfusion.
  • It should be noted that these therapies are primarily for the treatment of large vessel disease, and that many patients suffer from poor perfusion within smaller vessels that cannot be treated with conventional therapies.
  • The delivery of angiogenic growth factors to the heart via the coronary arteries by catheter techniques, or by implantable controlled release matrices, can create new capillary vascular growth within the myocardium. Recent work has shown substantial increases in muscular flow in a variety of in vivo experimental models with growth factors such as Tumor Angiogenic factor (TAF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and acidic fibroblast growth factor (aFGF). The methods of delivering these agents to the heart include implantable controlled release matrices such as ethylene vinyl acetate copolymer (EVAC), and sequential bolus delivery into the coronary arteries. Recently similar techniques have been attempted in peripheral vessels in human patients with the primary difficulty being systemic effects of the agents delivered.
  • U.S. Pat. No. 5,244,460 issued to Unger describes a method of introducing growth factors over time by delivering them through fluid catheters into the coronary arteries, but this does not result in efficient delivery of these agents to the ischemic tissue. If these or other agents are delivered to the coronary artery, a region of tissue that is equivalent to that supplied by the artery will receive the therapeutic agents. This may be substantially more tissue than is in need of local drug delivery therapy. Further, if a vessel is occluded, the growth factors will act in the tissue which the coronary arteries successfully perfuse. As the underlying problem of ischemic tissue is poor perfusion, excess growth factor must be delivered in order to obtain the desired effects in the poorly perfused tissue. Further, growth factors may cause unwanted angiogenesis in tissues where inappropriately delivered. The cornea is described by Unger as such a location, but perhaps more critical is inappropriate delivery of these factors to the brain. Further, placement of delivery devices within these coronary arteries as Unger describes tends to obstruct these arteries and may augment occlusive thrombosis formation. There is a significant need for minimizing the amount of growth factors for introducing angiogenesis by delivering these agents only to the site where they are most needed.
  • There are complications with clinically acceptable procedures where special devices for delivering agents to ischemic tissue will be useful. After opening vessels using PTCA, the vessels often lose patentcy over time. This loss of patentcy due to re-stenosis may be reduced by appropriate pharmacological therapy in the region of the artery. There is a need for new techniques that will enable pharmacological therapy to reduce the incidence of restenosis. Arrhythmogenic sites Cardiac arrhythmias are abnormal rhythmic contractions of the myocardial muscle, often introduced by electrical abnormalities, or irregularities in the heart tissue, and not necessarily from ischemic tissue. In a cardiac ablation procedure, the arrhythmogenic region is isolated or the inappropriate pathway is disrupted by destroying the cells in the regions of interest. Using catheter techniques to gain venous and arterial access to the chambers of the heart, and possibly trans septal techniques, necrotic regions can be generated by destroying the tissue locally. These necrotic regions effectively introduce electrical barriers to problematic conduction pathways.
  • U.S. Pat. No. 5,385,148 issued to Lesh describes a cardiac imaging and ablation catheter in which a helical needle may be used to deliver fluid ablative agents, such as ethanol, at a depth within the tissue to achieve ablation. Lesh further describes a method of delivering a pharmacological agent to the tissue just before performing the chemical ablation procedure to temporarily alter the conduction of the tissue prior to performing the ablation. Such temporary alteration of tissue has the advantage of allowing the physician to evaluate the results of destructive ablation in that region prior to actually performing the ablation. This method of ablation has the advantage that the ablative fluid agents are delivered to essentially the same tissue as the temporary modifying agents. However, with ablative fluid agents it is difficult to control the amount of tissue which is destroyed—especially in a beating heart, and ablative RF energy is in common use because of its reproducible lesions and ease of control. There is a need for an ablation catheter that uses a single structure within the heart wall for both temporary modification of tissue conductivity by delivery of therapeutic agents at a depth within the tissue, and delivery of RF energy.
  • U.S. Pat. No. 5,527,344 issued to Arzbaecher and incorporated by reference herein, describes a pharmacological atrial defibrillator and method for automatically delivering a defibrillating drug into the bloodstream of a patient upon detection of the onset of atrial arrhythmias in order to terminate the atrial arrhythmias. By delivering agents to a blood vessel, Arzbaecher requires systemic effects to be achieved in order to terminate the atrial arrhythmias. The advantages of local drug delivery are absent from the system described. There is a need for a system and method to transiently treat atrial arrhythmias by local delivery of pharmacological agents which affect the excitation of the cardiac tissue locally.
  • Many patents describe systems for delivering anti inflammatory agents to the endocardial surface of the heart. Such surface delivery is less viable for regions at a depth within the tissue. Further, because of the volume of fluid moving by the inner surfaces of the heart, higher concentrations may be required at the surface to counteract the effects of dilution. These higher doses result in greater likelihood of problematic systemic effects from the therapeutic agents. Delivering agents within the tissue will minimize the dilution of agents, and decrease the possibility of the agents being delivered to inappropriate sites. This is particularly important with growth factors whose systemic affects are not well documented, just as it is important for antiarrhythmic agents whose pro-arrhythmia systemic effects have been recognized. There is a need for a means to deliver agents to ischemic and arrhythmogenic sites within the myocardium.
  • To deliver substances at a depth within the heart, U.S. Pat. Nos. 5,447,533 and 5,531,780 issued to Vachon describe pacing leads having a stylet introduced anti inflammatory drug delivery dart and needle advanceable from the distal tip of the electrode. U.S. Pat. No. 5,002,067 issued to Berthelson describes a helical fixation device with a groove to provide a path to introduce anti-inflammatory drug to a depth within the tissue. U.S. Pat. No. 5,324,325 issued to Moaddeb describes a myocardial steroid releasing lead whose tip of the rigid helix has an axial bore filled with a therapeutic medication such as a steroid or steroid based drug. None of these patents provides a means for site specific delivery of agents as all applications of the drug delivery systems are at the location selected for pacing. None of these provides a means or method for delivering agents to ischemic or infarcted tissues. Only Vachon and Moaddeb provide a means for effectively delivering the anti-inflammatory agents to a depth within the myocardium. U.S. Pat. No. 5,551,427 issued to Altman describes a catheter system capable of delivering drugs to the heart at a depth within the heart tissue.
  • U.S. Pat. No. 5,431,649 issued to Mulier describes a hollow helical delivery needle to infuse the heart tissue with a conductive fluid prior to ablation to control the lesion size produced. The system does not have drug delivery capabilities.
  • None of the prior art includes the use of macromolecular controlled release matrices such as ethylene vinyl acetate copolymer to deliver agents with large molecular weights to a depth within the heart tissue.
  • OBJECTS AND ADVANTAGES
  • In general it is an object of the present invention to provide a biocompatible drug delivery catheter which will improve the ability to deliver drugs to a depth within the heart tissue.
  • Another object of the invention is the delivery of growth factors to a depth within the heart tissue over an extended period of time to increase collateral flow in poorly perfPat.uised tissue.
  • Yet another object of the invention is to provide a permanently implantable system that will enable transient delivery of pharmacological agents to a depth within the heart tissue such that cardiac arrhythmias may be terminated.
  • It is also an object of the invention to provide a combination drug delivery and ablation catheter that will enable a region of the heart tissue to be modified pharmacologically prior to performing RF ablation at a depth within the heart tissue.
  • It is a further object of the invention to provide catheters with implantable osmotic pumps at their distal ends that deliver pharmacological agents to a depth within the myocardium.
  • Another object of the invention is to provide catheters with controlled release matrices at their distal ends that deliver pharmacological agents to a depth within the heart tissue.
  • A further object of the invention is to provide catheters with fluid pathways from proximally located reservoirs which may deliver fluids to a depth within the myocardium, with an electrical conductor to sense the heart so an external device may determine when to deliver pharmacological therapy to a depth within the heart tissue.
  • A further object of the invention is to provide catheters with fluid pathways from proximally located reservoirs which may deliver fluids to a depth within the myocardium, with a high conductivity electrical conductor capable of delivering RF therapy to the heart from the metallic structure used to deliver drugs to the heart.
  • Yet another object of the invention is to provide catheters with a means to clear the agents from a catheter and replace them with other agents.
  • Further objects and advantages of this invention will become apparent from a consideration of the drawings and ensuing description.
  • DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a is a partial cross sectional view of a drug delivery catheter.
  • FIG. 1 b is a cross sectional view of the proximal portion of a dual lumen drug delivery catheter.
  • FIG. 1 c is a partial cross sectional view of the distal portion of a drug delivery catheter with a hollow fixation helix.
  • FIG. 2 is a partial cross sectional view of the distal portion of a drug delivery catheter with a short needle located in the axis of the helical fixation device.
  • FIG. 3 a is a partial cross sectional view of the distal portion of a drug delivery catheter which incorporates an osmotic pump.
  • FIG. 3 b is a partial cross sectional view of the distal portion of a drug delivery catheter which incorporates an osmotic pump.
  • FIG. 4 is a partial sectional view of a distal portion of a drug delivery catheter.
  • FIG. 5 a is a partial sectional view of the distal portion of a drug delivery catheter with a rate control barrier.
  • FIG. 5 b shows a partially sectioned view of the distal portion of a drug delivery catheter with a second lumen for stylet use during implantation.
  • FIG. 5 c is a transverse section of the catheter in FIG. 5 b.
  • FIG. 6 is a partial sectional view of a subcutaneous injection port, and a drug delivery catheter.
  • FIG. 7 is a partial sectional view of the distal end of a drug delivery catheter.
  • FIG. 8 is a partial sectional view of a filled helical drug delivery fixation means.
  • FIG. 8 a is a transverse section of the fixation means in FIG. 8.
  • FIG. 9 is a partial sectioned view of the distal end of a drug delivery catheter.
  • FIG. 10 a is a partial sectioned view of a drug delivery catheter with a nitinol transient delivery means.
  • FIG. 10 b is a partial cross sectional view of the distal portion of drug delivery catheter with a vapor pressure transient delivery means.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • New concepts for delivering agents for the treatment of heart failure, ischemia, arrhythmias, and restenosis are disclosed. The main embodiments consist of transvenous or transarterial catheter delivery techniques for delivering agents directly to a chosen site within the heart at a depth within the heart tissue. Hollow helical delivery devices, needle delivery devices, and implantable controlled release matrices may be inserted such that metabolic agents, anti ischemic agents, growth factors, antiarrhythmic agents, anti-inflammatory agents anti-proliferative agents, gene therapy preparations, and combinations of these agents may be delivered directly to the tissue that can benefit most from these agents.
  • These drug delivery structures may be made from different materials depending upon whether the device is to be used chronically or acutely. For example, metal components in the preferred implantable embodiments, formed of a Platinum Iridium alloy consisting of ninety percent Platinum and ten percent Iridium, typically are replaced with 316L surgical stainless steels in the acute embodiments. Likewise implantable grades of silicone and polyurethane are replaced with polyurethanes, polyolefins, fluoropolymers, nylon, and the like in the acute uses of the devices. Herein the term catheter is used to describe both chronically and acutely implantable systems.
  • FIG. 1 a shows a first cardiac drug delivery catheter with a sectional view of the proximal end. A pin 2 is shown mechanically crimped at a crimp 6 to an electrically conductive helical coil 8. Crimp 6 is typically covered by a compliant polymer molding 4 which may form a seal with a catheter port on a drug delivery reservoir or pumping means 16. Such a reservoir, shown schematically, may be implanted subcutaneously or located outside the patient. A line 18 represents a fluid coupling of reservoir 16 to lumen 12, which enables delivery of fluid treatment agents from the reservoir to fixation end 24. Further molding 4 and a catheter body or sheath 14 may have external sealing rings to provide fluid tight seals with such ports. Pin 2 connects to an internal tubing 10 with a lumen 12 which extends the entire length of the catheter to the distal end 22 and allows for fluid agents to be delivered through a fluid pathway in fixation end 24. The catheter body or sheath 14, 20, and 22 covers the coil 8 along the entire length of the delivery system distal to crimp 4 such that rotation of pin 2 or crimp 4 relative to proximal catheter body 14 rotates coil 8 within catheter body 14, 20, and 22 and deploys fixation mechanisms at fixation end 24. The central lumen 12 in some embodiments may also be used to pass a stylet for use during implantation to facilitate the implantation procedure.
  • The catheter shown in FIG. 1 a is made of permanently implantable materials, it has electrical continuity from end to end for sensing cardiac activity, it has a lumen for conveying fluidic agents along its length, and a hollow fixation means for delivering fluidic agents to a depth within the heart tissue.
  • Further as to the sensing of cardiac activity, a monitor and control device 26 is electrically coupled to pin 2 through a line 28, thus to enable a sensing of highly localized cardiac electrical activity at device 26. Cardiac activity can be recorded at device 26, e.g. stored in a memory chip (not shown). Further, sensed cardiac activity may be employed to provide controlling signals to reservoir 16 through a line 30, e.g. to. initiate or terminate the supplying of a fluid agent from the reservoir, responsive to sensing a predetermined activity or condition in cardiac tissue proximate fixation end 24. The materials selected are suited for permanent implantation to provide for transient drug delivery driven by a proximal reservoir and energy source. For example, catheter body 14, 20, and 22 is an implant grade polyurethane or silicone, and the distal fixation mechanism at fixation end 24 is a platinum iridium alloy. The catheter has a single electrode to facilitate implantation by sensing the electrical potential at the implant site. This combination achieves the advantages of ease of implantation, and delivery of fluidic agents to a depth within the heart from a proximally located reservoir.
  • In another embodiment, the monitor and control device 26 is not required. Instead, reservoir 16 pumps at a low, constant rate, supplying infusing agents to a depth within the myocardium, thus to locally apply selected agents, such as angiogenic growth factors, at a steady rate over an extended period, e.g. one week.
  • FIG. 1 b shows another embodiment of the proximal end of a catheter delivery system in which a stylet lumen 66 is provided for insertion of a stylet. Such an additional lumen may be useful to prevent contamination of an inner drug delivery tubing 62 during implantation. Inner tubing 62 is connected to a pin 52 at a connection 56, which may be performed simply by pulling tubing 62 over pin 52 at connection 56. An electrically conductive coil 60 surrounds tubing 62 and may be rotated relative to outer jacket or catheter body 58 of the delivery system. After implantation using a stylet in stylet lumen 66, pharmacological agents may be delivered to the heart by a fluid pathway defined by a delivery system lumen 64. In this specific embodiment, crimp 54 which connects pin 52 and coil 60 is not overmolded, and a single set of seals 70 are shown molded over the proximal end of catheter body 58. Seals 70 prevent migration of fluids into the catheter after connection with a catheter port in a drug delivery reservoir or pumping means. In one embodiment, the distal end of the drug delivery catheter shown in FIG. 1 b would be the distal embodiment shown in FIG. 5 b.
  • FIG. 1 c shows a partial cross sectional view of the distal portion of a delivery catheter which is to be implanted endocardially by the appropriate venous or arterial access. Here, a simple pathway for fluid to pass from a subcutaneous reservoir or delivery pump (not shown) through a deployable helical needle is provided. Helical coil 102 is multifilar, but could be single filar as well. The number of filars can be varied to determine the flexibility of the catheter as well as the coil's ability to transmit torque to fixation helix 114. The fixation helix is screwed into the heart by turning a coil 102 inside an outer catheter body 106. A fixed structure 130, on the inner wall of the catheter body 106, facilitates advancement and retraction of the fixation helix 114 by forcing the helical fixation structure 114 to advance from the distal end of the catheter when the central helical coil 102 and tube for drug delivery 104 are rotated counterclockwise. Fixed structure 130 is typically formed from a radio opaque material to assist the implanting physician in identifying when fixation helix 114 has been deployed. Fixed structure 130 also will retract the fixation helix 114 from the heart wall when the coil 102 is rotated clockwise. These directions could be reversed by varying the direction of the winding of the fixation helix 114. The helical coil 102 which provides torque to implant the fixation helix 114 is welded or crimped to a coupling structure or torque delivery structure 110 at a coil to torque delivery structure connection 128. Here, the coil is shown crimped at connection 128. Proximal stop 124, and distal stop 112 are raised portions on the inside of the catheter body 106, and prevent the fixation helix 114 from being extended or retracted too far. A fluid path is provided from the proximal end of the catheter (not shown) by tube for drug delivery 104 which connects to the tube fitting 126 of the hollow fixation helix 114. The hollow fixation helix 114 may have a number of small holes or helix apertures 116, 118, 120, 122 along its length where it is penetrated into the heart tissue. These holes provide a means for delivering agents into the heart tissue at a depth within the tissue. Helix tip 132 is sharp to facilitate penetration of the heart tissue, and acts as a fuPat.rther opening for the agents to migrate from the tissue. In some embodiments the helix apertures may be on only the distal portion of the helix to minimize the possibility of agents being delivered within the heart chambers. In other embodiments, the helix apertures are not present to maximize the structural integrity of the fixation helix. Where this is the case, agents are delivered to the heart from the aperture at the hollow helix tip 132. The fixation helix 114 is rigidly attached to the torque delivery structure 110 to provide means for advancement when coil 102 is rotated.
  • FIG. 1 c shows a means for delivering agents by a fluid path to a depth within the heart tissue, to provide a wide variety of agents by way of a fluid pathway to a depth within the tissue from a proximally located reservoir. Helix 114 acts as an electrode, with electrical energy being transmitted along helical coil 102 to and from fixation helix 114 by way of electrically conductive torque delivery structure 110. It can be viewed as the distal end of the implantable catheter whose proximal end is shown in FIG. 1 a or FIG. 1 b. In one embodiment, the device of FIG. 1 could be used for chronic delivery of antiarrhythmic agents to alter local conduction either continuously, or on demand based upon the signals sensed through fixation helix 114. Such algorithms have been described for pharmacological atrial defibrillation by Arzbaecher in U.S. Pat. No. 5,527,344. In other embodiments agents for a variety of disease states may be continuously infused by the fluid pathway to a specific site within the myocardium. The proximal end of the catheter may be connected to a drug pumping mechanism or to a proximally located reservoir. Such proximal devices may be implanted or located outside the patient. Access to implantable proximal devices for refilling agents is achieved with a subcutaneous port.
  • Transient delivery of pharmacological agents based upon demand requires the presence of electrical conductors along the length of the drug delivery catheter to monitor the electrical action of the heart, e.g. the heart rate as indicated by a time-dependent voltage. Delivering of agents upon demand locally alters the conduction or automaticity of the cardiac tissue and allows for the arrhythmia to be treated. Only a small amount of drug is required to treat a specific location within the tissue, which has substantial benefits. Small doses of antiarrhythmic agents minimize the need to refill the proximally located reservoir; and reduce the systemic effects from large drug doses as well as the effects of the agents on normally functioning cardiac tissue. In one application of this embodiment, the device is implanted in the right atrium at a location determined to be most likely to terminate a patients supraventricular arrhythmia. A subcutaneous infusion pump is triggered by the electrical activity of the heart, and a very small region of tissue receives local drug delivery for a preprogrammed duration. A small region of heart is then modified such that cardiac excitation wavefronts are altered by the tissue treated. This provides substantial advantages to patients. Typical of the drugs delivered are antiarrhythmic agents such as those described in U.S. Pat. No. 5,551,427 issued to Altman.
  • In another embodiment, the device in FIG. 1 c is an acute catheter made of nonimplantable materials. Catheter body 106 is formed of polyurethane or a fluoropolymer such as ETFE or PTFE; helical fixation structure 114, and torque delivery structure 110 are made of Titanium or 316L stainless steel. Such a catheter is used for acute ablation procedures in which antiarrhythmic agents are delivered to temporarily alter the conduction of the heart at the site of the implanted helix. Electrical mapping and stimulation measurements are made to determine if the region is appropriate to be ablated. If the region is not appropriate the device is removed and repositioned. If the region treated by the antiarrhythmic agents which affect tissue conduction is desired to be ablated, RF energy is delivered from the electrically active helix to a large surface electrode, such as that used in electrocautery. Such an electrode is shown schematically in FIG. 1 a as a patch electrode 32 that can be in contact with the patient's skin outside the body. A conductor 34 electrically couples electrode 32 with monitor and control device 26, whereby device 26 is employed in a known manner to utilize a circuit including conductors 28 and 34, electrode 32, pin 2, crimp 6, coil 8 and a fixation element at the distal end of the coil, to generate an RF current through tissue between the fixation element and electrode 32. The region ablated is that near the surface of the implanted helix. The helical coil 102 is highly conductive to enable RF energy to be conducted to the distal fixation structure to allow ablation of the region immediately at the fixation structure. Such a high conductivity coil can be formed from a number of wires wrapped in parallel in which each wire has a high conductivity silver core jacketed by an MP35N non corrosive alloy. This catheter provides for both temporary modification of tissue conductivity by delivery of therapeutic agents to a depth within the tissue, and delivery of RF energy from the same structure.
  • FIG. 2 shows another distal portion of a delivery catheter for endocardial placement. The operation is similar to that just described. However, here the fixation structure 202 is solid and does not provide a fluid path for delivery of agents. The fluid pathway is instead provided by a centrally located hollow needle 204. Apertures could also be made along the needle to provide more exposure to the tissue within the heart wall. Fluid agents flow through connecting tube 104, inside the hollow needle 204, and out through apertures in the surface (not shown) and the needle tip 206. Agents are delivered via the needle to a depth within the tissue. Thus, needle 204 provides a tissue penetrating element distinct from the fixation element, whereas in FIG. 1 c the penetrating element and fixation element are the same, i.e. helix 114. The solid fixation structure 202 advances in the same manner as described in FIG. 1, and may be rigidly attached to the torque delivery structure 110 by a weld 208. Other methods of connection are possible. The primary advantage of this design is that the solid helical fixation structure 202 is structurally more robust than that of the hollow structure shown in FIG. 1 c. This facilitates implantation of the structure.
  • Other embodiments which incorporate osmotic pumps, controlled release matrices, membrane barriers, and catheter based transient delivery means increase the ability to control the delivery of agents to a depth within the heart tissue. They have substantial advantages in delivering agents such as growth factors and gene therapy preparations in that very small amounts of the agents are effective, the delivery is controlled over time, and the agents are delivered to a depth within the heart.
  • FIG. 3 a shows an osmotic pump located at distal end of a catheter to drive therapeutic agent into heart tissue using a needle 318. Alternatively a hollow helix fluid transport system as described can be employed. Agents may be delivered via the fluid pathway previously described, through the check valve 302, and into the drug volume or drug reservoir 304. After the drug reservoir 304 is full, agents migrate out the needle tip 320, and apertures 322. Reservoir 304 may be loaded before, during, or after implantation from the proximal end of the drug delivery catheter. Once advanced into the heart tissue, diffusion of a liquid across the semipermeable membrane 312 occurs because of an osmotic salt 310. As this salt expands with hydration, pressure is exerted against the flexible barrier 306 and the rigid osmotic pump housing 308. The expansion constricts the drug volume 304. As check valve 302 is closed to reverse flow, the agents are forced through the delivery structure and into the heart wall. The pathway to needle tip 320 includes proximal needle apertures 316 and proximal needle opening 324 within the reservoir 304. The rigid support 314 supports the fixation helix and the needle delivery structure.
  • Placing an osmotic pump directly at the site where agents are delivered has the benefit of limiting the amount of agent in the system. In devices where the agent in the filling tube can be removed, the site specific osmotic pump does not require a long length of tubing filled with pharmacological agent. This may be particularly useful for agents whose systemic effects are undesirable or unknown. To deliver agents by a fluid pathway along the length of a catheter system requires a length of tubing to be filled with the appropriate agent. Although minimizing the cross sectional area of such a tube reduces excessive amounts of agents, putting the pump at the site for delivery eliminates the problem. Placing the osmotic device at the end of the catheter tube provides the advantageous means for follow-up delivery after the pump has delivered all of the agents in the reservoir 304. Further, only a very small amount of agent is required and the osmotic pump is placed on a catheter at the site for delivery. A catheter based osmotic pump as in FIG. 3 a may be filled proximally after implant, and agents may be altered during delivery. Such delivery techniques have substantial advantages for macromolecules such as growth factors and genetic material. Further, they may allow for very controlled delivery of microsphere or micelle encapsulated agents.
  • The drug reservoir 304 can contain either a solution or a solid formulation in a semipermeable housing with controlled water permeability. The drug is activated to release in solution form at a constant rate through a special delivery orifice (e.g. either 316 or 322). The release of drug molecules or encapsulated drug molecules from this type of controlled release drug delivery system is caused by osmotic pressure and controlled at a rate determined by the water permeability and the effective surface area of the semipermeable housing as well as the osmotic pressure gradient. Devices which use hydrodynamic pressure gradients are similar except the semipermeable membrane is replaced by an opening, and the osmotic salt is replaced by an absorbent and swellable hydrophilic laminate.
  • FIG. 3 b shows a partially sectional view of another embodiment of the distally located osmotic pump. Here a check valve 402 is located at the proximal end of a needle 404 which extends through drug volume or reservoir 304. Needle 404 provides more structural stability to the drug delivery device and guarantees a fluid pathway to the delivery needle tip 320 even after the osmotic action has driven all of the agent out of the drug volume 304. Further, a section of a seal 406 is shown attached to the inside of the catheter body. Osmotic pump housing 308 is moveably contained within seal 406, which acts to prevent migration of fluids into the catheter body.
  • FIG. 4 shows another embodiment of a cardiac drug delivery system. Here the fixation mechanism consists of a needle 484 with apertures 486 that penetrates the myocardium and is held in place by barbs 466. In a chronic implant barb 466 may be composed of either a rigid metallic alloy or a biodegradable polymer. If a biodegradable material is used, long term tissue attachments will maintain fixation with the heart, and the barb 466 will not cause undue trauma should the drug delivery system need to be explanted.
  • In addition, FIG. 4 shows a multilumen catheter and valve system for the filling of reservoir 462. Agents are delivered along the fluid path defmed by a filling lumen 452 in a bitumen tubing 450 such that unidirectional check valve 456, shown here as a ball check valve, is opened allowing agents to flow through lumen 458 of tube 460 and out the distal end of tube 480. The ball check valve has a sphere in a generally conical tube which allows unidirectional flow by obstructing the smaller diameter fluid pathway to reverse flow and not obstructing the larger diameter circular pathway of the open flow direction in various embodiments it could be replaced with a reed check valve, a hinged plate check valve, or the equivalent. After the reservoir 462 is filled, the fluid will open check valve 472 and flow out clearing lumen 468 in bitumen tube 450. This filling action will force ball check valve 470 closed. After filling, the remaining agent in the bitumen tube may be cleared by delivering sterile distilled water, which may contain anticoagulants such as heparin to assure long term patentcy of the catheter lumens, to clearing lumen 468. This clearing fluid will force check valve 472 closed, and check valve 470 open such that agents may be flushed from the bitumen tube and replaced with the distilled water or other flushing agents. If the system is chronically implanted, such a bitumen tube and series of valves would allow one to fill the reservoir 462 and clear the bitumen tube 450 after implant. Further, because the distal end of the tube 480 allows for filling of the reservoir 462 from the distal end, agents may be changed merely by filling via filling lumen 452 which will force the existing agents out through proximal reservoir exit 474, through valve 472 and clearing lumen 468. If the proximal end of such a bilumen delivery system were connected to a dual port subcutaneous reservoir (not shown) agents would be injected into one port while withdrawn from the second port.
  • In this delivery catheter, the distal housing also acts as an osmotic delivery system with semi permeable membrane 496, hydrophilic salt or agent 476, and flexible polymer barrier 464 allowing for controlled delivery of agents over a period of time. After the expiration of the osmotic energy source, agents may be delivered via the fluid pathway by an external pumping means if desired. The valve housing 454 houses the three unidirectional valves 456, 470, and 472, and provides tube fittings 488 and 490 for connection to the bitumen tubing. This valve housing 454 is also attached by a crimp 494 to the coil 492. This structure is assembled from the separate components and combined. Alternatively, separate valves could be fit into openings in a simpler metallic form, and the whole mechanically and hermetically attached to the rigid osmotic pump housing 478. Rigid support 482 is fixed to needle 484, and may also have structural elements which enter into the region of the hydrophilic salt, and possibly attach to the valve housing 454.
  • FIG. 5 a shows partially in section an embodiment where a membrane or rate controlling barrier 506 stands between the agent reservoir 502 and the apertures 518 in the proximal end of the delivery needle 520 which would allow the agents to be delivered to the distal end of the delivery needle 524, and through the apertures 522. The needle could be replaced with a hollow helical delivery device as shown in FIG. 1 c if desired. An optional controlled release structure 508 provides chronic delivery of agents to the implant site. As this agent diminishes, new agents can be provided through the connecting tube and check valve 402, such that rate of release is governed by control barrier 506. Barrier 506 is shown here with substantial thickness, but it could be formed of a simple membrane, a membrane reinforced with a substantially porous structure, such as a laminate of expanded polytetrafluoroethylene (ePTFE), or any other structure which could be used to govern the rate of drug delivery to the side of the barrier connected by a fluid pathway to the tissue to be treated. The design of the control release barrier would be customized for the agents to be delivered and may be intentionally designed to specify a rate of delivery substantially different from that which the optional control release structure 508. Needle plug 516 prevents flow through the needle lumen, while maintaining a rigid axial support, and could be formed of an inert polymer or metallic material. Rigid support 510 acts to support axial location of needle 524 and may be a mechanical base for the helical fixation means. Controlled release structure 508 could be composed of a macromolecular controlled release matrix such as EVAC housing a growth factor such as TAF, bFGF, or aFGF.
  • In another preferred embodiment of FIG. 5 a, controlled release structure 508 would be left out and the space would be filled with pharmacological agents and act as a reservoir for acute delivery immediately after implantation. The fluid path for subsequent agents would then include tubing 104, check valve 402, proximal needle 512 and proximal apertures 514 into agent reservoir 502, contained by drug reservoir housing 504. The fluid agent then passes through rate control barrier 506 into the fluid reservoir.
  • In other embodiments of FIG. 5 a, the control barrier 506 could be electrically activated to allow rapid delivery of positive pressure and agent delivery from one side to the other. In this electrically activated embodiment, the optional control release structure or acute reservoir 508 could merely deliver agents acutely to preserve the viability of the fluid pathway for the time when therapy is deemed necessary. Acute delivery of antithrombolytics and anti-inflammatory agents would limit blockages and tissue inflammation resulting from the implantation of the structure in the heart wall and improve the ability of a transient system to deliver agents quickly and effectively to the region within the tissue. An electrically controlled barrier could be fashioned much like any electrically controlled microvalve.
  • FIG. 5 b is a partially sectional view of the drug delivery system described in FIG. 5 a which incorporates a separate stylet lumen 552 within the same catheter body 550. Such a stylet lumen accommodates a removable wire element to allow the implanting physician to control the shape of the device to guide it to the appropriate site. This additional lumen 552 allows the drug delivery tubing to travel the length of the coil in its own lumen 554. Although shown here as a continuous part of catheter body 550, stylet end stop 556 usually is attached as a separate component. FIG. 5 c shows the diameter of stylet lumen 552 to be substantially smaller than lumen 554. These lumens may change depending upon the requirements for different applications. Such an additional lumen for stylet use could easily be combined with any of the drug delivery systems presented here. This additional lumen will prevent the lumen of the drug delivery tubing 104 from getting obstructed with body fluids during stylet use, prevent damage to tubing 104 by the stylet, and allow the materials of both stylet and tubing 104 to be chosen without regard to the requirements of the other.
  • FIG. 6 is a partially sectioned view of one preferred embodiment of a subcutaneous reservoir structure 626 and a drug delivery catheter 628. Subcutaneous reservoir structure 626 may be connected to the proximal end of the delivery catheters shown. Subcutaneous reservoir structure 626 consists of a housing 602 whose reservoir 606 may be filled with a fluid pharmacological agent. The agent is introduced by transcutaneous injection into the reservoir 606 through the polymer injection barrier 604. This barrier is typically composed of silicone rubber such that it creates a seal after removal of the filling needle. In addition, the housing 602 is typically constructed of titanium, polyurethane, or other known rigid biocompatible and nonreactive materials.
  • FIG. 6 shows a means for connecting the drug delivery catheter to the subcutaneous reservoir, a constant pressure pumping means, or automatic infusion pump. Subcutaneous reservoir structure 626 has a port 610 which accepts the proximal end of delivery catheter 628 such that the region of separation 622 between the crimp structure 620 and proximal end of the jacket body 614 is completely within port 610. This prevents fluids from entering the separation 622 which allows the coil and inner tubing 624 to rotate relative to the jacket body 614 for advancement of fixation structure 616 and needle delivery system 618. After the proximal end is inserted into port 610 of subcutaneous reservoir structure 626, a set screw may be advanced within threads 608 to secure the catheter in position by applying force to pin 612. This set screw connection to the pin is common in devices used to deliver electrical therapy to the heart, and could be used to perform an electrical connection to the fixation means 616 or needle 618 in order to sense the electrical activity of the tissue. This electrical signal could be monitored by devices with algorithms similar to those designed to deliver electrical therapy to the heart, except that instead of electrical therapy they introduce pharmacologic therapy.
  • FIG. 7 shows another embodiment of an acute drug delivery system. The catheter body 702 houses a lumen 704 for fluid transport of therapeutic agents and a lumen 706 for stylet use during implantation. Lumen 704 travels the length of the delivery catheter and connects to needle delivery structure 714. During implantation through the vasculature, blood soluble coating 710, e.g. as in U.S. Pat. No. 4,827,940 issued to Mayer, completely protects the vasculature from the sharp elements of the fixation helix 712 and the needle delivery structure 714. Blood soluble coatings such as sugars may be used. After the appropriate heart chamber is accessed, the physician waits for the coating 710 to dissolve. The coating may be combined with a radio opaque material such as barium sulfate to identify better when this has been accomplished. After the coating 710 has dissolved, the physician implants the fixation helix 712 by rotating the entire catheter about its own axis. Torque is delivered from the catheter body 702 to the fixation helix 712 by the embedded portion 708 of the fixation helix. This embedded region can be manufactured using molding and bonding technology. The principle advantage of this device is the small cost of manufacturing such a simple design with no moving parts.
  • FIG. 8 shows a hollow fixation helix 802 with apertures 804 along its length. FIG. 8 a shows the hollow helix to be filled with a second material 810. Second material 810 in the preferred embodiment is a controlled release polymer matrix filled with a therapeutic agent for extended delivery of agents through apertures 804 in fixation helix 802. In one embodiment the controlled release matrix is comprised of silicone rubber and the agent to be delivered is lidocaine. In another embodiment the agent may be amiodorone HCL. In another embodiment, the controlled release matrix is EVAC and the agent is aFGF. Other variations are also possible. After implantation of the structure within the heart wall by penetration of helix tip 808, the rest of the helix is rotated such that all apertures 804 are within the tissue. Agents then migrate from the controlled release matrix to the tissue in which it is implanted. Such a controlled release matrix filling of the hollow core which penetrates the heart could be pursued with other penetrating structures as well.
  • FIG. 9 shows a drug delivery system with VEGF in an EVAC matrix 908 housed in a reservoir defined by cylinder 906, and ends 904 and 914. In the preferred embodiment, these are nonpermeable, although in other embodiments permeability may be desirable. End 904 acts both to transmit torque to fixation helix 916, but also as a stop for a stylet (not shown) which may be used during implantation down the coil lumen 902. After implantation of the drug delivery catheter, body fluids migrate through apertures in distal needle 920 and into a reservoir through a proximal region 912 of the needle and dissolve pharmacological agents in acute dosage 910 which may be present to counter inflammation associated with implantation. Over time, growth factors are delivered via needle 920 to a depth within the heart. Note that the absence of a tube for agent delivery enables stylet use during implantation. In variations on this embodiment, other controlled release means could be housed within a semi permeable structure that would allow increased fluid transport to assist in delivery of agents through needle 920 to a depth within the heart wall.
  • FIG. 10 a shows another drug delivery catheter in which agents may be delivered transiently to a depth within the tissue. Here, helical coil consists of four coradial wires which are electrically isolated from one another by a layer of insulation. The electrical insulation allows a current pathway to be defined which allows current to flow through electrical connection 1018 from two of the coradial wires and into Nitinol thermally activated shape memory ribbon or band 1020, which wraps around flexible polymer barrier 1010 as shown in section. Current flowing through Nitinol ribbon 1020 completes its circuit to the other two coradial wires at electrical connection 1002 to torque delivery structure 1004 via conduction through a connection to support structure 1012 which is electrically connected to needle 1028. Insulating structure 1032 separates the two electrical connection regions on torque delivery structure 1004 and allows current to pass through ribbon 1020. If the electrical resistance of the Nitinol is sufficiently high, ohmic heating causes a constricting shape change upon the flexible polymer barrier 1010. Contained within flexible polymer barrier 1010 is a partially porous polymer controlled release matrix structure 1022 such as silicone rubber containing lidocaine, which upon compression by the Nitinol ribbon, forces agents out of the controlled release matrix 1022 and into the needle 1028 within the reservoir 1026, then out the distal region 1016 of the needle into the heart.
  • FIG. 10 b shows another transient drug delivery structure in which a reservoir contains a fluid whose vapor pressure provides the energy to delivery therapeutic agents. As in FIG. 10 a, the different filars in the helical coil, such as filar 1068, are electrically insulated from one another such that two independent electrical connections may be made at a crimp 1050 and a crimp 1072 which are separated from each other by electrically insulating barrier 1070. The electrical connections made at crimp 1050 and 1072 have an electrical path between them which is defined by resistive heating element 1052 which passes through a reservoir 1056. Within reservoir 1056 is a fluid gas mixture which provides a constant pressure at human body temperature via a plate 1058 to a drug matrix 1060. If drug matrix 1060 is a substantially porous controlled release matrix, the pores surrounding the matrix will be filled with relatively high concentration of agents in fluids. As electrical energy is delivered along the two independent electrical conductors to resistive heating element 1052, the temperature of the fluid within reservoir 1056 increases. As reservoir housing 1066 and support structure 1064 are rigid and noncompliant, this increases the pressure within reservoir 1056 to cause expansion of bellows 1054 and apply pressure to the controlled release matrix 1060. This forces the concentrated fluid from within the porous controlled release matrix into proximal end of needle delivery system 1074 and out through the distal end of the needle into the heart wall. Such vapor pressure energy sources have been used in infusion pumps such as an infusion pump available from Infusaid of Norwood, MA. However, that system has not been implanted on a catheter, nor does that pressure system provide a thermal element to increase the temperature within the charging fluid and thus deliver the pressure transiently. In addition to the porous matrix, there is a soluble anti-thrombogenic and anti inflammatory agent for use in acute dosage form 1062 which surrounds proximal length of needle 1074, while still leaving the end free for agent administration. Such acute dosage forms may be very useful for guaranteeing the long term outcome of such controlled delivery systems by minimizing the response of the tissue to the trauma of implantation.
  • A method for delivering therapy using a combined drug delivery ablation catheter proceeds as follows. Initially the arrhythmogenic site is located using techniques common to those in the field of cardiac electrophysiology. The delivery system is inserted into the appropriate site within the heart by the internal or external jugulars, cephalic vein, subclavian vein, femoral artery, or the other vascular delivery routes. Then, the drug delivery structure is implanted at the arrhythmogenic site supply an appropriate agent for altering the local conduction properties. After implantation, agents are delivered and the effect on the arrhythmogenic site is evaluated by electrical techniques such as mapping. If the location is appropriate, and the agents appear to terminate the critical arrhythmia, RF energy is delivered to the tissue by way of the same structure used to deliver the agents to the heart. If the position is inappropriate and the local pharmacological agents do not correct for the arrhythmia, the device is repositioned, and the procedure repeated.
  • A method for transient treatment of supraventricular arrhythmias using a chronically implantable transient drug delivery catheter proceeds as follows. After electrophysiologists have specified the appropriate region for implantation based upon the patient's cardiac electrical action, a catheter is implanted at this site to deliver antiarrhythmic agents at a depth within the heart transiently, as well as to sense the electrical activity near the device. The catheter is then connected to an external controller and power source, which determines suitability of therapy and delivers energy to a device such as those described in FIGS. 10 a and 10 b for transient delivery of pharmacological agents, or to a device such as that shown in FIG. 1 c coupled to a proximally located pumping means. The device then senses cardiac activity through the surface of the drug delivery structure. When the heart experiences an arrhythmic event, the controller identifies the event and activates the energy source which delivers the drug to the heart. This drug modifies the selected area of tissue and either terminates the arrhythmia, or substantially reduces the magnitude of the required electrical therapy. If the arrhythmia does not terminate, the pump may deliver a secondary dosage, or trigger an external electrical therapy device. If no arrhythmia is sensed, the device is maintained in a monitoring mode.
  • Thus the different embodiments of the invention provide a means to effectively deliver agents at a depth within the myocardium to provide a new means for delivering pharmacological therapy to specific locations within the heart. These delivery systems will allow therapies for ischemic tissue, arrhythmogenic sites, and other cardiac disease to be delivered over an extended period of time through a chronic implant, or rapidly over a short period of time during an acute procedure. They enable controlled delivery of small amounts of macromolecular agents such as growth factors, transient drug delivery to the tissue for treating cardiac arrhythmias, and may be used with other cardiac devices.
  • Many other variations are possible. For example, the flow of liquid agents maybe driven by implantable infusion pumps with a variety of energy sources, and the device could be made from different biocompatible materials. Other examples include distally located electrically activated piezoelectric crystals as energy sources for drug delivery, and distally located ultrasound transducers for implantation using ultrasound imaging. In addition, in the embodiments where unipolar sensing through the drug delivery structure is insufficient, it is a simple task to add another electrode to enable bipolar sensing.
  • Catheters with a straight cylindrical lumen from one end to the other could be used with a thin bundle of optical fibers passed through the lumen to photoablatively create channels within the heart for improving the flow of pharmacological agents within the heart. In other variations, the thin optical fiber could be replaced with a thin RF electrode structure which could literally burn channels within the tissue. Such procedures could be viewed as a combined transmyocardial revascularization (TMR) and drug delivery. For example, after a catheter is implanted and agents are delivered to minimize reflow damage to the heart, simple TMR could be introduced with a centrally placed optical fiber. Subsequent to the TMR, angiogenic growth factors could be introduced.
  • In other embodiments, the devices described may be used for acute delivery of metabolic agents, and anti-ischemic agents to poorly perfused tissue just prior to introducing reflow. The agents improve the health of the poorly perfused tissue and minimize the amount of reflow injury introduced by the white blood cells. In another embodiment the devices described may be used to deliver specific antiarrhythmic agents over a time course of days to weeks while physicians determine whether an implantable system is appropriate. In a another embodiment, the catheters described may be used to deliver gene therapy at a depth in the diseased myocardium over a period of days to weeks.
  • Further, the delivery of the agents could be performed with appropriately modified catheter shapes such that curves are located to effect a certain position within the heart. Such curves in a catheter could be molded into place, or held in place by plastic deformation of the helical coil in the region it is desired. Such curved structures may provide improved access to certain regions within the right atrium, left atrium, right ventricle and left ventricle.
  • Further, the implantable versions of the different catheters could have their fixation mechanisms coated with radioactive agents such as Phosphorous 32 to emit beta radiation for the minimization of tissue growth on the fixation structures. This has particular advantages for catheters meant to be implanted for durations longer than a few days, to be removed after the therapy has been delivered.
  • Further, acute embodiments of this device could incorporate standard sensor technologies for measuring pH and P 02 within the heart chamber or even within the myocardium, and mapping electrodes could be placed along the distal portion of the catheter body to facilitate implantation relative to measured electrical signals through the myocardium.
  • Accordingly, the scope of the invention should be determined not by the embodiments illustrated, but by the appended claims and their legal equivalents.

Claims (36)

1-38. (canceled)
39. An apparatus for treating tissue in the region of the heart to reduce the incidence of restenosis, including:
an elongate, flexible, biocompatible carrier having a proximal end, a distal end, and an internal volume containing a fluid including a pharmacological agent adapted to reduce the incidence of restenosis in a body lumen, wherein the carrier is adapted for intraluminal conveyance to a treatment site in the region of the heart; and
a tissue penetrating structure supported with respect to the distal end of the carrier, adapted for a penetration of tissue at the treatment site to a depth within surrounding tissue to secure the tissue penetrating structure within the tissue, and further to effect a local delivery of the fluid from the internal volume into the surrounding tissue;
wherein the carrier is operable at said proximal end to cause said penetration.
40. The apparatus of claim 39 wherein:
the carrier comprises a catheter, and the internal volume comprises a catheter lumen running axially along the catheter between the proximal and distal ends.
41. The apparatus of claim 40 further including:
a fluid source coupled to the proximal end of the catheter to supply the fluid to the tissue penetrating structure via the catheter lumen.
42. The apparatus of claim 39 wherein:
the internal volume comprises a reservoir at the distal end of the carrier.
43. The apparatus of claim 39 wherein:
the tissue penetrating structure includes a tissue penetrating element that is hollow to define an internal passage having a proximal opening to receive the fluid from the internal volume, and at least one distal opening to deliver the fluid to the surrounding tissue when the penetrating element is penetrated in said tissue.
44. The apparatus of claim 43 wherein:
the penetrating element comprises a helical coil adapted to so secure the tissue penetrating structure.
45. The apparatus of claim 43 wherein:
the tissue penetrating element comprises a substantially linear needle, and the tissue penetrating structure further includes a fixation element adapted to so secure the tissue penetrating structure.
46. The apparatus of claim 39 wherein:
the pharmacological agent comprises an anti-ischemic agent.
47. The apparatus of claim 39 further including:
an elongate and flexible electrical conductor coextensive with the carrier and electrically coupled to the penetrating element, wherein the penetrating element is electrically conductive.
48. An apparatus for treating tissue in the region of the heart to reduce the incidence of reflow injury, including:
an elongate, flexible, biocompatible carrier having a proximal end, a distal end, and an internal volume containing a fluid including a pharmacological agent adapted to reduce the incidence of reflow injury in a body lumen, wherein the carrier is adapted for intraluminal conveyance to a treatment site in the region of the heart; and
a tissue penetrating structure supported with respect to the distal end of the carrier, adapted for a penetration of tissue at the treatment site to a depth within surrounding tissue to secure the tissue penetrating structure relative to said tissue, and fPat.urther to effect a local delivery of the fluid from the internal volume into the surrounding tissue;
wherein the carrier is operable at the proximal end to cause said penetration.
49. The apparatus of claim 48 wherein:
the carrier comprises a catheter, and the internal volume comprises a catheter lumen running axially along the catheter between the proximal and distal ends.
50. The apparatus of claim 49 further including:
a fluid source coupled to the proximal end of the catheter to supply the fluid to the tissue penetrating structure via the catheter lumen.
51. The apparatus of claim 48 wherein:
the internal volume comprises a reservoir at the distal end of the carrier.
52. The apparatus of claim 48 wherein:
the tissue penetrating structure includes a tissue penetrating element that is hollow to define an internal passage having a proximal opening to receive the fluid from the internal volume, and at least one distal opening to deliver the fluid to the surrounding tissue when the penetrating element is penetrated in said tissue.
53. The apparatus of claim 52 wherein:
the penetrating element comprises a helical coil.
54. The apparatus of claim 52 wherein:
the tissue penetrating element comprises a substantially linear needle, and the tissue penetrating structure further includes a fixation element adapted to so secure the tissue penetrating structure.
55. The apparatus of claim 48 wherein:
the pharmacological agent is selected from the group of agents consisting of: metabolic agents, anti-ischemic agents, and their combinations.
56. The apparatus of claim 48 further including:
an elongate and flexible electrical conductor coextensive with the carrier and electrically coupled to the penetrating element, wherein the penetrating element is electrically conductive.
57. A process for treating tissue in the region of the heart, to reduce the incidence of restenosis, including:
identifying a treatment site situated in the region of the heart and subject to a risk of restenosis;
using an elongate, flexible carrier that supports at its distal end a fluid delivery structure including a distal tissue penetrating structure, to intraluminally deliver the fluid delivery structure to the treatment site and to effect a penetration of the tissue penetrating structure to a depth within tissue at the treatment site, whereby the tissue penetrating structure is surrounded by the tissue and the fluid delivery structure is secured relative to the tissue by virtue of said penetration;
selecting a treatment agent adapted to reduce the incidence of restenosis; and
after effecting said penetration, delivering a fluid including the selected treatment agent from an internal volume of the carrier through the penetrating structure into the surrounding tissue.
58. The process of claim 57 wherein:
said delivering comprises conveying the fluid to the tissue penetrating structure via a carrier lumen running axially along the carrier.
59. The process of claim 57 wherein:
the fluid delivery structure defines an internal passage having at least one distal opening in the tissue penetrating structure, and said delivering comprises delivering the fluid through the internal passage towards the at least one distal opening.
60. The process of claim 57 further including:
providing a reservoir near the distal end of the carrier for containing the fluid, wherein said delivering comprises providing the fluid from the reservoir to the fluid delivery structure.
61. The process of claim 57 wherein:
selecting the treatment agent comprises selecting an anti-ischemic agent.
62. The process of claim 57 wherein:
identifying a treatment site comprises selecting a treatment site within a body lumen.
63. The process of claim 57 wherein:
identifying the treatment site comprises selecting an intramyocardial site for delivery of the fluid.
64. The process of claim 57 wherein:
said delivering comprises effecting a sustained delivery of the treatment agent that is localized to the surrounding tissue.
65. The process of claim 57 wherein:
said identifying a treatment site includes identifying a treatment site within the heart.
66. A process for treating tissue in the region of the heart, to reduce the incidence of reflow injury, including:
identifying a treatment site situated in the region of the heart and subject to a risk of reflow injury;
using an elongate, flexible carrier that supports at its distal end a fluid delivery structure including a distal tissue penetrating structure, to intraluminally deliver the fluid delivery structure to the treatment site and to effect a penetration of the tissue penetrating structure to a depth within tissue at the treatment site, whereby the tissue penetrating structure is surrounded by the tissue and the fluid delivery structure is secured relative to the tissue by virtue of said penetration;
selecting a treatment agent adapted to reduce the incidence of reflow injury; and
after effecting said penetration, delivering a fluid including the selected treatment agent from an internal volume of the carrier through the penetrating structure into the surrounding tissue.
67. The process of claim 66 wherein:
said delivering comprises conveying the fluid to the tissue penetrating structure via a carrier lumen running axially along the carrier.
68. The process of claim 66 wherein:
the fluid delivery structure defines an internal passage having at least one distal opening in the tissue penetrating structure, and said delivering comprises delivering the fluid through the internal passage towards the at least one distal opening.
69. The process of claim 66 further including:
providing a reservoir near the distal end of the carrier for containing the fluid, wherein said delivering comprises providing the fluid from the reservoir to the fluid delivery structure.
70. The process of claim 66 wherein:
selecting the treatment agent comprises selecting an agent from the group consisting of: metabolic agents, anti-ischemic agents, and their combinations.
71. The process of claim 66 wherein:
identifying a treatment site comprises selecting a treatment site within a body lumen.
72. The process of claim 66 wherein:
identifying the treatment site comprises selecting an intramyocardial site for delivery of the fluid.
73. The process of claim 66 wherein:
said delivering comprises effecting a sustained delivery of the treatment agent that is localized to the surrounding tissue.
US11/110,143 1997-03-13 2005-04-20 Cardiac drug delivery system and method of use Abandoned US20050215991A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/816,850 US6086582A (en) 1997-03-13 1997-03-13 Cardiac drug delivery system
US09/260,641 US6358247B1 (en) 1997-03-13 1999-03-02 Cardiac drug delivery system
US10/101,301 US7104988B2 (en) 1997-03-13 2002-03-19 Cardiac drug delivery system
US11/110,143 US20050215991A1 (en) 1997-03-13 2005-04-20 Cardiac drug delivery system and method of use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/110,143 US20050215991A1 (en) 1997-03-13 2005-04-20 Cardiac drug delivery system and method of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/101,301 Division US7104988B2 (en) 1997-03-13 2002-03-19 Cardiac drug delivery system

Publications (1)

Publication Number Publication Date
US20050215991A1 true US20050215991A1 (en) 2005-09-29

Family

ID=25221772

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/816,850 Expired - Lifetime US6086582A (en) 1997-03-13 1997-03-13 Cardiac drug delivery system
US09/260,641 Expired - Lifetime US6358247B1 (en) 1997-03-13 1999-03-02 Cardiac drug delivery system
US10/101,301 Expired - Lifetime US7104988B2 (en) 1997-03-13 2002-03-19 Cardiac drug delivery system
US11/110,143 Abandoned US20050215991A1 (en) 1997-03-13 2005-04-20 Cardiac drug delivery system and method of use

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/816,850 Expired - Lifetime US6086582A (en) 1997-03-13 1997-03-13 Cardiac drug delivery system
US09/260,641 Expired - Lifetime US6358247B1 (en) 1997-03-13 1999-03-02 Cardiac drug delivery system
US10/101,301 Expired - Lifetime US7104988B2 (en) 1997-03-13 2002-03-19 Cardiac drug delivery system

Country Status (1)

Country Link
US (4) US6086582A (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080405A1 (en) * 2003-03-26 2005-04-14 Bischof John C. Thermal surgical procedures and compositions
US20070093818A1 (en) * 2005-08-03 2007-04-26 Lutz Biedermann Bone anchoring device
WO2007084929A3 (en) * 2006-01-18 2007-12-13 Cannuflow Inc Helical extravasation minimization device
US20080114297A1 (en) * 2006-11-13 2008-05-15 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US20100043787A1 (en) * 2008-08-21 2010-02-25 Fine David H Systems and devices for generating nitric oxide
US20100185143A1 (en) * 2009-01-21 2010-07-22 Palo Alto Research Center Incorporated Sensor system for drug delivery device, drug delivery device having the same and method of using the same
US20100204678A1 (en) * 2009-02-12 2010-08-12 Mir Imran Skin penetrating device and method for subcutaneous solid drug delivery
US7892229B2 (en) 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US8016823B2 (en) 2003-01-18 2011-09-13 Tsunami Medtech, Llc Medical instrument and method of use
US8147532B2 (en) 2007-10-22 2012-04-03 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8322335B2 (en) 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8444636B2 (en) * 2001-12-07 2013-05-21 Tsunami Medtech, Llc Medical instrument and method of use
US20130218124A1 (en) * 2011-11-21 2013-08-22 Incube Labs, Llc Myocardial drug delivery apparatus and method
US8574226B2 (en) 2000-12-09 2013-11-05 Tsunami Medtech, Llc Method for treating tissue
US8579893B2 (en) 2005-08-03 2013-11-12 Tsunami Medtech, Llc Medical system and method of use
US8579888B2 (en) 2008-06-17 2013-11-12 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
US8579892B2 (en) 2003-10-07 2013-11-12 Tsunami Medtech, Llc Medical system and method of use
US8721632B2 (en) 2008-09-09 2014-05-13 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US8772030B2 (en) 2003-07-31 2014-07-08 Universita Degli Studi Di Roma “La Sapienza” Cardiac stem cells and methods for isolation of same
US8900223B2 (en) 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
US9050076B2 (en) 2004-11-16 2015-06-09 Uptake Medical Corp. Device and method for lung treatment
US20150224281A1 (en) * 2012-09-11 2015-08-13 Native Cardiovascular Llc Device and methods for targeted tissue drug delivery
US9161801B2 (en) 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US9561068B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561067B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9700365B2 (en) 2008-10-06 2017-07-11 Santa Anna Tech Llc Method and apparatus for the ablation of gastrointestinal tissue
US9782211B2 (en) 2013-10-01 2017-10-10 Uptake Medical Technology Inc. Preferential volume reduction of diseased segments of a heterogeneous lobe
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
US10064697B2 (en) 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US10179019B2 (en) 2014-05-22 2019-01-15 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
US10238446B2 (en) 2010-11-09 2019-03-26 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
USD845467S1 (en) 2017-09-17 2019-04-09 Uptake Medical Technology Inc. Hand-piece for medical ablation catheter
US10299856B2 (en) 2014-05-22 2019-05-28 Aegea Medical Inc. Systems and methods for performing endometrial ablation

Families Citing this family (301)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125136A (en) * 1996-01-08 2003-07-31 Impulse Dynamics Nv Electrical cardiac muscle controller method and apparatus
US8825152B2 (en) 1996-01-08 2014-09-02 Impulse Dynamics, N.V. Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue
US8321013B2 (en) 1996-01-08 2012-11-27 Impulse Dynamics, N.V. Electrical muscle controller and pacing with hemodynamic enhancement
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
WO1995003843A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US6723082B1 (en) * 1995-05-10 2004-04-20 Sam G. Payne Delivery catheter system for heart chamber
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US7167748B2 (en) 1996-01-08 2007-01-23 Impulse Dynamics Nv Electrical muscle controller
DE69733815T2 (en) * 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Probe for excavation
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6547787B1 (en) * 1997-03-13 2003-04-15 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US7505807B1 (en) * 1997-05-15 2009-03-17 Regents Of The University Of Minnesota Magnetic resonance apparatus for use with active electrode and drug deliver catheter
US8346363B2 (en) 1999-03-05 2013-01-01 Metacure Limited Blood glucose level control
US6775574B1 (en) * 1997-11-07 2004-08-10 Medtronic, Inc. Method and system for myocardial infarction repair
US6651670B2 (en) * 1998-02-13 2003-11-25 Ventrica, Inc. Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
EP1102560A4 (en) * 1998-08-07 2003-03-12 Infinite Biomedical Technologi Implantable myocardial ischemia detection, indication and action technology
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
US7491232B2 (en) 1998-09-18 2009-02-17 Aptus Endosystems, Inc. Catheter-based fastener implantation apparatus and methods with implantation force resolution
US9320503B2 (en) * 2001-11-28 2016-04-26 Medtronic Vascular, Inc. Devices, system, and methods for guiding an operative tool into an interior body region
US7637932B2 (en) * 2001-11-28 2009-12-29 Aptus Endosystems, Inc. Devices, systems, and methods for prosthesis delivery and implantation
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
US6463334B1 (en) 1998-11-02 2002-10-08 Cardiac Pacemakers, Inc. Extendable and retractable lead
DE60043534D1 (en) 1999-02-04 2010-01-28 Pluristem Ltd METHOD AND DEVICE FOR CONTAINMENT AND EXPANSION OF STEM CELLS hematopoietic AND / OR progenitor cells
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8700161B2 (en) 1999-03-05 2014-04-15 Metacure Limited Blood glucose level control
US8019421B2 (en) 1999-03-05 2011-09-13 Metacure Limited Blood glucose level control
US6702811B2 (en) 1999-04-05 2004-03-09 Medtronic, Inc. Ablation catheter assembly with radially decreasing helix and method of use
US7171263B2 (en) * 1999-06-04 2007-01-30 Impulse Dynamics Nv Drug delivery device
US7190997B1 (en) 1999-06-04 2007-03-13 Impulse Dynamics Nv Drug delivery device
US7092753B2 (en) * 1999-06-04 2006-08-15 Impulse Dynamics Nv Drug delivery device
US6719805B1 (en) * 1999-06-09 2004-04-13 C. R. Bard, Inc. Devices and methods for treating tissue
US6516749B1 (en) * 1999-06-18 2003-02-11 Salasoft, Inc. Apparatus for the delivery to an animal of a beneficial agent
AU6519100A (en) * 1999-08-05 2001-03-05 Biocardia, Inc. A system and method for delivering thermally sensitive and reverse-thermal gelation matrials
US6709427B1 (en) * 1999-08-05 2004-03-23 Kensey Nash Corporation Systems and methods for delivering agents into targeted tissue of a living being
US6738661B1 (en) * 1999-10-22 2004-05-18 Biosynergetics, Inc. Apparatus and methods for the controllable modification of compound concentration in a tube
US6993385B1 (en) 1999-10-25 2006-01-31 Impulse Dynamics N.V. Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof
WO2001030445A1 (en) 1999-10-25 2001-05-03 Impulse Dynamics N.V. Cardiac contractility modulation device having anti-arrhythmic capabilities and a method of operating thereof
US7758521B2 (en) * 1999-10-29 2010-07-20 Medtronic, Inc. Methods and systems for accessing the pericardial space
US7386341B2 (en) * 2000-03-13 2008-06-10 Arrow International, Inc. Instrument and method for delivery of anaesthetic drugs
US6478776B1 (en) 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
US6585716B2 (en) * 2000-04-05 2003-07-01 Biocardia, Inc. Method of treating the heart
US6613017B1 (en) * 2000-08-08 2003-09-02 Scimed Life Systems, Inc. Controlled depth injection device and method
US6595958B1 (en) * 2000-08-08 2003-07-22 Scimed Life Systems, Inc. Tortuous path injection device and method
US6893421B1 (en) 2000-08-08 2005-05-17 Scimed Life Systems, Inc. Catheter shaft assembly
IL154769D0 (en) * 2000-09-06 2003-10-31 Univ Johns Hopkins Cardiac arrhythmia treatment methods
US20090175790A1 (en) * 2000-09-06 2009-07-09 The Johns Hopkins University Cardiac arrhythmia treatment methods and biological pacemaker
US9931503B2 (en) 2003-03-10 2018-04-03 Impulse Dynamics Nv Protein activity modification
WO2002032347A2 (en) 2000-10-16 2002-04-25 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
AUPR148400A0 (en) * 2000-11-14 2000-12-07 Cochlear Limited Apparatus for delivery of pharmaceuticals to the cochlea
US20020077687A1 (en) * 2000-12-14 2002-06-20 Ahn Samuel S. Catheter assembly for treating ischemic tissue
US7232460B2 (en) * 2001-04-25 2007-06-19 Xillus, Inc. Nanodevices, microdevices and sensors on in-vivo structures and method for the same
EP1409510A4 (en) * 2001-04-27 2004-09-08 Univ Johns Hopkins Biological pacemaker
US7727229B2 (en) * 2001-05-01 2010-06-01 C.R. Bard, Inc. Method and apparatus for altering conduction properties in the heart and in adjacent vessels
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
US6702744B2 (en) * 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
WO2003003948A1 (en) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Anti-arrhythmia devices and methods of use
US6835193B2 (en) 2001-07-10 2004-12-28 Myocardial Therapeutics, Inc. Methods for controlled depth injections into interior body cavities
US6796963B2 (en) * 2001-07-10 2004-09-28 Myocardial Therapeutics, Inc. Flexible tissue injection catheters with controlled depth penetration
DE10137102A1 (en) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalent vaccine against diseases caused by papilloma viruses, processes for their preparation and their use
US20030028231A1 (en) * 2001-08-01 2003-02-06 Cardiac Pacemakers, Inc. Radiopaque drug collar for implantable endocardial leads
US8934968B2 (en) * 2001-08-03 2015-01-13 Cardiac Pacemakers, Inc. Neurostimulation and coronary artery disease treatment
US7481759B2 (en) * 2001-08-03 2009-01-27 Cardiac Pacemakers, Inc. Systems and methods for treatment of coronary artery disease
US6728574B2 (en) 2001-10-19 2004-04-27 Medtronic, Inc. System and method for patient-controlled relief of pain associated with electrical therapies
US6936040B2 (en) * 2001-10-29 2005-08-30 Medtronic, Inc. Method and apparatus for endovenous pacing lead
US7776025B2 (en) 2001-10-29 2010-08-17 Edwards Lifesciences Corporation Method for providing medicament to tissue
US7308303B2 (en) 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
US7252819B2 (en) 2001-11-08 2007-08-07 The Regents Of The University Of California Methods and compositions for correction of cardiac conduction disturbances
US7187980B2 (en) * 2001-11-09 2007-03-06 Oscor Inc. Cardiac lead with steroid eluting ring
US20030105409A1 (en) 2001-11-14 2003-06-05 Donoghue John Philip Neurological signal decoding
US8075570B2 (en) * 2001-11-28 2011-12-13 Aptus Endosystems, Inc. Intraluminal prosthesis attachment systems and methods
US20050177180A1 (en) 2001-11-28 2005-08-11 Aptus Endosystems, Inc. Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ
US20050070992A1 (en) 2001-11-28 2005-03-31 Aptus Endosystems, Inc. Prosthesis systems and methods sized and configured for the receipt and retention of fasteners
CN101352375A (en) * 2001-11-28 2009-01-28 阿普特斯内系统公司 Endovascular aneurysm repair system
CN101466316B (en) 2005-10-20 2012-06-27 阿普特斯内系统公司 Devices systems and methods for prosthesis delivery and implantation including the use of a fastener tool
EP1448117B1 (en) 2001-11-28 2013-05-22 Aptus Endosystems, Inc. Endovascular aneurysm repair system
US20070073389A1 (en) 2001-11-28 2007-03-29 Aptus Endosystems, Inc. Endovascular aneurysm devices, systems, and methods
US8231639B2 (en) * 2001-11-28 2012-07-31 Aptus Endosystems, Inc. Systems and methods for attaching a prosthesis within a body lumen or hollow organ
EP2349086B1 (en) 2008-10-16 2017-03-22 Medtronic Vascular, Inc. Devices and systems for endovascular staple and/or prosthesis delivery and implantation
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US20030161816A1 (en) * 2001-12-07 2003-08-28 Fraser John K. Systems and methods for treating patients with processed lipoaspirate cells
US7771716B2 (en) * 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US7595043B2 (en) * 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US20060204556A1 (en) * 2001-12-07 2006-09-14 Cytori Therapeutics, Inc. Cell-loaded prostheses for regenerative intraluminal applications
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
JP2005538945A (en) * 2002-05-08 2005-12-22 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア System and method for treating cardiac arrhythmias in fibroblasts
CA2487280A1 (en) * 2002-05-08 2003-11-20 The Regents Of The University Of California System and method for forming a substantially non-ablative cardiac conduction block
US20060002898A1 (en) * 2002-05-08 2006-01-05 Lee Randall J Methods and compositions for correction of cardiac conduction disturbances
AU2003239957A1 (en) * 2002-06-04 2003-12-19 Cyberkinetics, Inc. Optically-connected implants and related systems and methods of use
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
US20040044329A1 (en) * 2002-08-29 2004-03-04 Trudell Leonard A. Catheter for cardiac injection and method for delivery of therapeutic agents to specified tissues
US7400931B2 (en) * 2002-09-18 2008-07-15 Cardiac Pacemakers, Inc. Devices and methods to stimulate therapeutic angiogenesis for ischemia and heart failure
US7682312B2 (en) * 2002-09-20 2010-03-23 Advanced Circulatory Systems, Inc. System for sensing, diagnosing and treating physiological conditions and methods
WO2004030630A2 (en) * 2002-10-02 2004-04-15 The Johns Hopkins University Focal calcium channel modulation
US7103418B2 (en) * 2002-10-02 2006-09-05 Medtronic, Inc. Active fluid delivery catheter
US7212851B2 (en) * 2002-10-24 2007-05-01 Brown University Research Foundation Microstructured arrays for cortex interaction and related methods of manufacture and use
AU2002952663A0 (en) * 2002-11-14 2002-11-28 Western Sydney Area Health Service An intramural needle-tipped surgical device
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US6932804B2 (en) * 2003-01-21 2005-08-23 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
CN102156571B (en) 2003-02-10 2013-07-24 N-特莱格有限公司 Touch detection for a digitizer
EP1605875A3 (en) 2003-03-03 2005-12-28 Sinus Rhythm Technologies, Inc. Electrical block positioning devices and methods of use therefor
US9398967B2 (en) * 2004-03-02 2016-07-26 Syntach Ag Electrical conduction block implant device
EP1605866B1 (en) 2003-03-03 2016-07-06 Syntach AG Electrical conduction block implant device
JP2006519663A (en) 2003-03-10 2006-08-31 インパルス ダイナミックス エヌヴイ Device and method for delivering electrical signals to regulate gene expression in cardiac tissue
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
EP1462141B1 (en) * 2003-03-26 2006-09-20 Terumo Kabushiki Kaisha Catheter with puncture sensor
JP4698128B2 (en) * 2003-03-28 2011-06-08 テルモ株式会社 Catheter with a puncture sensor
US7186247B2 (en) * 2003-04-04 2007-03-06 Medtronic, Inc. Apparatus and system for delivery of drug therapies
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US20050021091A1 (en) * 2003-04-23 2005-01-27 Laske Timothy G. System for the delivery of a biologic therapy with device monitoring and back-up
WO2004098511A2 (en) * 2003-05-01 2004-11-18 Sinus Rhythm Technologies, Inc. Methods and devices for creating electrical block at specific targeted sites in cardia tissue
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
WO2004098565A2 (en) 2003-05-02 2004-11-18 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
CA2526792A1 (en) * 2003-06-05 2004-12-16 Centelion Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US7945337B2 (en) * 2003-08-27 2011-05-17 Medtronic, Inc. High impedance and low polarization electrode
US7156843B2 (en) * 2003-09-08 2007-01-02 Medtronic, Inc. Irrigated focal ablation tip
US7155292B2 (en) * 2003-09-25 2006-12-26 Cardiac Pacemakers, Inc. Active fixation assembly for an implantable device
US7953499B2 (en) * 2003-09-30 2011-05-31 Cardiac Pacemakers, Inc. Drug-eluting electrode
US7147657B2 (en) * 2003-10-23 2006-12-12 Aptus Endosystems, Inc. Prosthesis delivery systems and methods
US7266414B2 (en) * 2003-10-24 2007-09-04 Syntach, Ag Methods and devices for creating electrical block at specific sites in cardiac tissue with targeted tissue ablation
US20050143589A1 (en) * 2003-11-09 2005-06-30 Donoghue John P. Calibration systems and methods for neural interface devices
SE526861C2 (en) * 2003-11-17 2005-11-15 Syntach Ag The tissue lesion creating device and a set of devices for treatment of disorders in the heart rhythm regulation system
US20050113744A1 (en) * 2003-11-21 2005-05-26 Cyberkinetics, Inc. Agent delivery systems and related methods under control of biological electrical signals
US7751877B2 (en) * 2003-11-25 2010-07-06 Braingate Co., Llc Neural interface system with embedded id
US7245973B2 (en) * 2003-12-23 2007-07-17 Cardiac Pacemakers, Inc. His bundle mapping, pacing, and injection lead
US7647097B2 (en) * 2003-12-29 2010-01-12 Braingate Co., Llc Transcutaneous implant
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
EP1703916A2 (en) * 2004-01-13 2006-09-27 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US20050165452A1 (en) * 2004-01-28 2005-07-28 Medtronic, Inc. Antithrombogenic medical device
US20050203366A1 (en) * 2004-03-12 2005-09-15 Donoghue John P. Neurological event monitoring and therapy systems and related methods
US8244371B2 (en) 2005-03-18 2012-08-14 Metacure Limited Pancreas lead
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US8349001B2 (en) * 2004-04-07 2013-01-08 Medtronic, Inc. Pharmacological delivery implement for use with cardiac repair devices
US20050267061A1 (en) * 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US7534775B2 (en) * 2004-04-08 2009-05-19 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
WO2006023130A2 (en) * 2004-08-12 2006-03-02 Surmodics, Inc. Biodegradable controlled release bioactive agent delivery device
US20060049957A1 (en) * 2004-08-13 2006-03-09 Surgenor Timothy R Biological interface systems with controlled device selector and related methods
EP1827207A2 (en) * 2004-10-04 2007-09-05 Cyberkinetics Neurotechnology Systems, Inc. Biological interface system
WO2006042246A2 (en) * 2004-10-08 2006-04-20 Syntach Ag Two-stage scar generation for treating atrial fibrillation
US8489189B2 (en) * 2004-10-29 2013-07-16 Medtronic, Inc. Expandable fixation mechanism
US20060095077A1 (en) * 2004-10-29 2006-05-04 Tronnes Carole A Expandable fixation structures
EP1898991B1 (en) 2005-05-04 2016-06-29 Impulse Dynamics NV Protein activity modification
US8010192B2 (en) 2004-12-20 2011-08-30 Cardiac Pacemakers, Inc. Endocardial pacing relating to conduction abnormalities
US8423139B2 (en) 2004-12-20 2013-04-16 Cardiac Pacemakers, Inc. Methods, devices and systems for cardiac rhythm management using an electrode arrangement
US8050756B2 (en) 2004-12-20 2011-11-01 Cardiac Pacemakers, Inc. Circuit-based devices and methods for pulse control of endocardial pacing in cardiac rhythm management
US8010191B2 (en) 2004-12-20 2011-08-30 Cardiac Pacemakers, Inc. Systems, devices and methods for monitoring efficiency of pacing
US8014861B2 (en) 2004-12-20 2011-09-06 Cardiac Pacemakers, Inc. Systems, devices and methods relating to endocardial pacing for resynchronization
AR047851A1 (en) 2004-12-20 2006-03-01 Giniger Alberto German A new pacemaker that restores or preserves physiological electrical conduction of the heart and an application method
US8326423B2 (en) 2004-12-20 2012-12-04 Cardiac Pacemakers, Inc. Devices and methods for steering electrical stimulation in cardiac rhythm management
US8290586B2 (en) 2004-12-20 2012-10-16 Cardiac Pacemakers, Inc. Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device
US8005544B2 (en) 2004-12-20 2011-08-23 Cardiac Pacemakers, Inc. Endocardial pacing devices and methods useful for resynchronization and defibrillation
US7901368B2 (en) * 2005-01-06 2011-03-08 Braingate Co., Llc Neurally controlled patient ambulation system
US8095209B2 (en) * 2005-01-06 2012-01-10 Braingate Co., Llc Biological interface system with gated control signal
US7991461B2 (en) * 2005-01-06 2011-08-02 Braingate Co., Llc Patient training routine for biological interface system
US20100023021A1 (en) * 2005-12-27 2010-01-28 Flaherty J Christopher Biological Interface and Insertion
US20060189899A1 (en) * 2005-01-10 2006-08-24 Flaherty J Christopher Joint movement apparatus
US20080140451A1 (en) * 2005-01-10 2008-06-12 Cytori Therapeutics, Inc. Devices and Methods for Monitoring, Managing, and Servicing Medical Devices
US20060189901A1 (en) * 2005-01-10 2006-08-24 Flaherty J C Biological interface system with surrogate controlled device
US7881780B2 (en) * 2005-01-18 2011-02-01 Braingate Co., Llc Biological interface system with thresholded configuration
US8078266B2 (en) 2005-10-25 2011-12-13 Voyage Medical, Inc. Flow reduction hood systems
US9510732B2 (en) * 2005-10-25 2016-12-06 Intuitive Surgical Operations, Inc. Methods and apparatus for efficient purging
US10064540B2 (en) * 2005-02-02 2018-09-04 Intuitive Surgical Operations, Inc. Visualization apparatus for transseptal access
US7918787B2 (en) * 2005-02-02 2011-04-05 Voyage Medical, Inc. Tissue visualization and manipulation systems
US7930016B1 (en) 2005-02-02 2011-04-19 Voyage Medical, Inc. Tissue closure system
US8137333B2 (en) 2005-10-25 2012-03-20 Voyage Medical, Inc. Delivery of biological compounds to ischemic and/or infarcted tissue
US9055906B2 (en) 2006-06-14 2015-06-16 Intuitive Surgical Operations, Inc. In-vivo visualization systems
US7860556B2 (en) * 2005-02-02 2010-12-28 Voyage Medical, Inc. Tissue imaging and extraction systems
US8221310B2 (en) * 2005-10-25 2012-07-17 Voyage Medical, Inc. Tissue visualization device and method variations
US8050746B2 (en) * 2005-02-02 2011-11-01 Voyage Medical, Inc. Tissue visualization device and method variations
US7860555B2 (en) 2005-02-02 2010-12-28 Voyage Medical, Inc. Tissue visualization and manipulation system
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) * 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US20060293737A1 (en) * 2005-06-22 2006-12-28 Cardiac Pacemakers, Inc. Multiple electrode implantable lead
US8892197B2 (en) * 2005-07-29 2014-11-18 Medtronic, Inc. Method and apparatus to control conduction through the heart to treat cardiac conditions
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
JP2009511064A (en) * 2005-10-14 2009-03-19 ザ ジョンズ ホプキンス ユニバーシティー Biological excitable cells
WO2007061530A1 (en) * 2005-10-14 2007-05-31 Cytori Therapeutics, Inc. Cell delivery catheters with distal tip high fidelity sensors
US20070106143A1 (en) * 2005-11-08 2007-05-10 Flaherty J C Electrode arrays and related methods
US20070106277A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Remote controller for substance delivery system
US8273071B2 (en) * 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US8083710B2 (en) * 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8992511B2 (en) * 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20070106275A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Reaction device controlled by RF control signal
US8273075B2 (en) 2005-12-13 2012-09-25 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic flow rate
US20080140057A1 (en) * 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
US7942867B2 (en) 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8936590B2 (en) * 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8303505B2 (en) * 2005-12-02 2012-11-06 Abbott Cardiovascular Systems Inc. Methods and apparatuses for image guided medical procedures
DE102005062658B3 (en) * 2005-12-28 2007-05-31 Osypka, Peter, Dr.-Ing. Device for occluding opening between two heart chambers formed by two overlapping tissue lobes in heart, has connecting mechanism which has screw catheter that dilates at its distal end and is movable into feed catheter
US20070156126A1 (en) * 2005-12-29 2007-07-05 Flaherty J C Medical device insertion system and related methods
US7751883B2 (en) * 2006-04-25 2010-07-06 Eugenio Picano System and method for promoting coronary angiogenesis
US20070282254A1 (en) * 2006-05-16 2007-12-06 Mina Chow Needle devices and methods
WO2007139551A1 (en) * 2006-05-30 2007-12-06 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells from adipose tissue
WO2008013863A2 (en) * 2006-07-26 2008-01-31 Cytori Therapeutics, Inc. Generation of adipose tissue and adipocytes
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US20090221955A1 (en) * 2006-08-08 2009-09-03 Bacoustics, Llc Ablative ultrasonic-cryogenic methods
US20080039727A1 (en) * 2006-08-08 2008-02-14 Eilaz Babaev Ablative Cardiac Catheter System
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080097476A1 (en) 2006-09-01 2008-04-24 Voyage Medical, Inc. Precision control systems for tissue visualization and manipulation assemblies
JP2010502313A (en) 2006-09-01 2010-01-28 ボエッジ メディカル, インコーポレイテッド Method and apparatus for the treatment of atrial fibrillation
US10004388B2 (en) * 2006-09-01 2018-06-26 Intuitive Surgical Operations, Inc. Coronary sinus cannulation
US9782258B2 (en) * 2006-09-08 2017-10-10 The Regents Of The University Of California Intramyocardial patterning for global cardiac resizing and reshaping
US20080103576A1 (en) * 2006-10-31 2008-05-01 Medtronic, Inc. Implantable medical elongated member including expandable fixation member
US7657326B2 (en) * 2006-11-08 2010-02-02 Cardiac Pacemakers, Inc. Cardiac lead with a retractable helix
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US20100185146A1 (en) * 2006-12-06 2010-07-22 Laura N. Dietch Drug delivery systems
US8758229B2 (en) * 2006-12-21 2014-06-24 Intuitive Surgical Operations, Inc. Axial visualization systems
US8131350B2 (en) * 2006-12-21 2012-03-06 Voyage Medical, Inc. Stabilization of visualization catheters
US8151790B2 (en) 2007-04-19 2012-04-10 Advanced Circulatory Systems, Inc. Volume exchanger valve system and method to increase circulation during CPR
US9352111B2 (en) 2007-04-19 2016-05-31 Advanced Circulatory Systems, Inc. Systems and methods to increase survival with favorable neurological function after cardiac arrest
WO2008133553A1 (en) * 2007-04-27 2008-11-06 St. Jude Medical Ab A medical implantable lead with, a header at a distal end and a marker thereon
JP2010524651A (en) 2007-04-27 2010-07-22 ボエッジ メディカル, インコーポレイテッド Steerable tissue visualization and manipulation the catheter with a complex shape
US8657805B2 (en) * 2007-05-08 2014-02-25 Intuitive Surgical Operations, Inc. Complex shape steerable tissue visualization and manipulation catheter
EP2155036B1 (en) * 2007-05-11 2016-02-24 Intuitive Surgical Operations, Inc. Visual electrode ablation systems
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US9149610B2 (en) 2007-05-31 2015-10-06 Abbott Cardiovascular Systems Inc. Method and apparatus for improving delivery of an agent to a kidney
US9364586B2 (en) * 2007-05-31 2016-06-14 Abbott Cardiovascular Systems Inc. Method and apparatus for improving delivery of an agent to a kidney
US9144509B2 (en) * 2007-05-31 2015-09-29 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090030276A1 (en) * 2007-07-27 2009-01-29 Voyage Medical, Inc. Tissue visualization catheter with imaging systems integration
US20090062790A1 (en) * 2007-08-31 2009-03-05 Voyage Medical, Inc. Direct visualization bipolar ablation systems
US8235985B2 (en) 2007-08-31 2012-08-07 Voyage Medical, Inc. Visualization and ablation system variations
US20090125022A1 (en) * 2007-11-12 2009-05-14 Voyage Medical, Inc. Tissue visualization and ablation systems
US20090143640A1 (en) * 2007-11-26 2009-06-04 Voyage Medical, Inc. Combination imaging and treatment assemblies
US20090143713A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor
US8858609B2 (en) * 2008-02-07 2014-10-14 Intuitive Surgical Operations, Inc. Stent delivery under direct visualization
US8801665B2 (en) * 2008-04-10 2014-08-12 Henry Ford Health System Apparatus and method for controlled depth of injection into myocardial tissue
EP2280756B1 (en) * 2008-04-29 2014-07-23 St. Jude Medical AB An implantable medical lead and a method of manufacturing thereof
US20090326572A1 (en) * 2008-06-27 2009-12-31 Ruey-Feng Peh Apparatus and methods for rapid tissue crossing
WO2010002633A1 (en) * 2008-07-03 2010-01-07 Cardiac Pacemakers, Inc. Helical fixation member with chemical elution capabilities
US9101735B2 (en) 2008-07-07 2015-08-11 Intuitive Surgical Operations, Inc. Catheter control systems
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
WO2010011930A2 (en) * 2008-07-24 2010-01-28 Boston Scientific Scimed, Inc. Various catheter devices for myocardial injections or other uses
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US8333012B2 (en) 2008-10-10 2012-12-18 Voyage Medical, Inc. Method of forming electrode placement and connection systems
US8894643B2 (en) 2008-10-10 2014-11-25 Intuitive Surgical Operations, Inc. Integral electrode placement and connection systems
US8996134B2 (en) * 2008-11-07 2015-03-31 W. L. Gore & Associates, Inc. Implantable lead
US8364281B2 (en) * 2008-11-07 2013-01-29 W. L. Gore & Associates, Inc. Implantable lead
US9468364B2 (en) 2008-11-14 2016-10-18 Intuitive Surgical Operations, Inc. Intravascular catheter with hood and image processing systems
WO2010062394A2 (en) * 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
EP2384222A2 (en) 2008-12-19 2011-11-09 Cardiac Pacemakers, Inc. Devices, methods, and systems including cardiac pacing
US20100256629A1 (en) * 2009-04-06 2010-10-07 Voyage Medical, Inc. Methods and devices for treatment of the ostium
JP5917392B2 (en) * 2009-05-01 2016-05-11 ビミニ テクノロジーズ リミテッド ライアビリティ カンパニー System for optimizing tissue and cell enrichment graft, methods and compositions
US9901347B2 (en) 2009-05-29 2018-02-27 Terus Medical, Inc. Biliary shunts, delivery systems, and methods of using the same
EP2327366B1 (en) 2009-11-30 2012-03-14 Sorin CRM SAS Kit for piercing the cardiac septum and implanting a transseptal probe, in particular a probe for detection/stimulation of a left cavity of the heart
US8197438B2 (en) * 2009-12-23 2012-06-12 Roche Diagnostics Operations, Inc. Medicinal fluid delivery systems and methods for priming the same
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
US9724266B2 (en) 2010-02-12 2017-08-08 Zoll Medical Corporation Enhanced guided active compression decompression cardiopulmonary resuscitation systems and methods
US8694071B2 (en) 2010-02-12 2014-04-08 Intuitive Surgical Operations, Inc. Image stabilization techniques and methods
US9814522B2 (en) 2010-04-06 2017-11-14 Intuitive Surgical Operations, Inc. Apparatus and methods for ablation efficacy
WO2011139691A1 (en) 2010-04-27 2011-11-10 Cardiac Pacemakers, Inc. His-bundle capture verification and monitoring
WO2011146069A1 (en) 2010-05-21 2011-11-24 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US10132303B2 (en) 2010-05-21 2018-11-20 Hewlett-Packard Development Company, L.P. Generating fluid flow in a fluidic network
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
US9395050B2 (en) * 2010-05-21 2016-07-19 Hewlett-Packard Development Company, L.P. Microfluidic systems and networks
US20130102858A1 (en) * 2010-06-18 2013-04-25 St. Jude Medical Ab Implantable sensor device and system
WO2012061161A1 (en) 2010-10-25 2012-05-10 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods
EP2665412B1 (en) 2011-01-17 2018-06-20 Biosynergetics, Inc. In-line flow meter
WO2012125273A2 (en) 2011-03-14 2012-09-20 Cardiac Pacemakers, Inc. His capture verification using electro-mechanical delay
JP2015500733A (en) 2011-12-19 2015-01-08 レスキューシステムズ インコーポレイテッドResqsystems,Inc. Intrathoracic pressure adjustment system and method for the treatment
US8546412B2 (en) * 2011-12-21 2013-10-01 Abbott Cardiovascular Systems, Inc. Methods of treating heart failure
RU2601906C2 (en) 2012-05-11 2016-11-10 Медтроник АФ Люксембург С.а.р.л. Catheter device containing blocks of several electrodes for renal neuromodulation and appropriate systems and methods
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
EP2719424B1 (en) * 2012-10-12 2015-04-08 Sorin CRM SAS Intraseptal probe for left ventricular stimulation
US9095321B2 (en) 2012-11-21 2015-08-04 Medtronic Ardian Luxembourg S.A.R.L. Cryotherapeutic devices having integral multi-helical balloons and methods of making the same
US9179974B2 (en) 2013-03-15 2015-11-10 Medtronic Ardian Luxembourg S.A.R.L. Helical push wire electrode
US9811634B2 (en) 2013-04-25 2017-11-07 Zoll Medical Corporation Systems and methods to predict the chances of neurologically intact survival while performing CPR
US20140358047A1 (en) 2013-05-30 2014-12-04 ResQSystems, Inc. End-tidal carbon dioxide and amplitude spectral area as non-invasive markers of coronary perfusion pressure and arterial pressure
US9151369B2 (en) * 2013-06-17 2015-10-06 Korea Institute Of Machinery & Materials Aerostatic air bearing, assembling method thereof, and aerostatic lead screw actuator using the same
US10265495B2 (en) 2013-11-22 2019-04-23 Zoll Medical Corporation Pressure actuated valve systems and methods
WO2016059639A1 (en) 2014-10-14 2016-04-21 Valtech Cardio Ltd. Leaflet-restraining techniques
JP2017086875A (en) * 2015-11-03 2017-05-25 バイオトロニック エスエー アンド カンパニー カーゲー Anchoring control system for medical devices
GB201611910D0 (en) 2016-07-08 2016-08-24 Valtech Cardio Ltd Adjustable annuloplasty device with alternating peaks and troughs
CA3040182A1 (en) * 2016-10-20 2018-04-26 Retrovascular, Inc. Method and device for enhanced composition delivery

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002067A (en) * 1989-08-23 1991-03-26 Medtronic, Inc. Medical electrical lead employing improved penetrating electrode
US5025036A (en) * 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids
US5236424A (en) * 1992-06-05 1993-08-17 Cardiac Pathways Corporation Catheter with retractable cannula for delivering a plurality of chemicals
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
US5324325A (en) * 1991-06-27 1994-06-28 Siemens Pacesetter, Inc. Myocardial steroid releasing lead
US5385148A (en) * 1993-07-30 1995-01-31 The Regents Of The University Of California Cardiac imaging and ablation catheter
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5840059A (en) * 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5846225A (en) * 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US5980516A (en) * 1993-08-27 1999-11-09 Medtronic, Inc. Method and apparatus for R-F ablation
US5997509A (en) * 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
US6004269A (en) * 1993-07-01 1999-12-21 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials, and ablating tissue
US6093177A (en) * 1997-03-07 2000-07-25 Cardiogenesis Corporation Catheter with flexible intermediate section
US6932804B2 (en) * 2003-01-21 2005-08-23 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US5447533A (en) * 1992-09-03 1995-09-05 Pacesetter, Inc. Implantable stimulation lead having an advanceable therapeutic drug delivery system
US5405376A (en) * 1993-08-27 1995-04-11 Medtronic, Inc. Method and apparatus for ablation
US5431649A (en) * 1993-08-27 1995-07-11 Medtronic, Inc. Method and apparatus for R-F ablation
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5527344A (en) * 1994-08-01 1996-06-18 Illinois Institute Of Technology Pharmacologic atrial defibrillator and method
US5609151A (en) * 1994-09-08 1997-03-11 Medtronic, Inc. Method for R-F ablation
US5575814A (en) * 1995-01-27 1996-11-19 Medtronic, Inc. Active fixation medical electrical lead having mapping capability
US5551427A (en) * 1995-02-13 1996-09-03 Altman; Peter A. Implantable device for the effective elimination of cardiac arrhythmogenic sites
US5827216A (en) * 1995-06-07 1998-10-27 Cormedics Corp. Method and apparatus for accessing the pericardial space
US5697951A (en) * 1996-04-25 1997-12-16 Medtronic, Inc. Implantable stimulation and drug infusion techniques
US6067988A (en) * 1996-12-26 2000-05-30 Eclipse Surgical Technologies, Inc. Method for creation of drug delivery and/or stimulation pockets in myocardium
US5999678A (en) * 1996-12-27 1999-12-07 Eclipse Surgical Technologies, Inc. Laser delivery means adapted for drug delivery
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US5972013A (en) * 1997-09-19 1999-10-26 Comedicus Incorporated Direct pericardial access device with deflecting mechanism and method
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025036A (en) * 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5002067A (en) * 1989-08-23 1991-03-26 Medtronic, Inc. Medical electrical lead employing improved penetrating electrode
US5324325A (en) * 1991-06-27 1994-06-28 Siemens Pacesetter, Inc. Myocardial steroid releasing lead
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
US5236424A (en) * 1992-06-05 1993-08-17 Cardiac Pathways Corporation Catheter with retractable cannula for delivering a plurality of chemicals
US6004269A (en) * 1993-07-01 1999-12-21 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials, and ablating tissue
US5385148A (en) * 1993-07-30 1995-01-31 The Regents Of The University Of California Cardiac imaging and ablation catheter
US5980516A (en) * 1993-08-27 1999-11-09 Medtronic, Inc. Method and apparatus for R-F ablation
US5840059A (en) * 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5846225A (en) * 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US6093177A (en) * 1997-03-07 2000-07-25 Cardiogenesis Corporation Catheter with flexible intermediate section
US5997509A (en) * 1998-03-06 1999-12-07 Cornell Research Foundation, Inc. Minimally invasive gene therapy delivery device and method
US6932804B2 (en) * 2003-01-21 2005-08-23 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858549B2 (en) 1998-03-27 2014-10-14 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US9204889B2 (en) 1998-03-27 2015-12-08 Tsunami Medtech, Llc Medical instrument and method of use
US8187269B2 (en) 1998-03-27 2012-05-29 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US8574226B2 (en) 2000-12-09 2013-11-05 Tsunami Medtech, Llc Method for treating tissue
US9615875B2 (en) 2000-12-09 2017-04-11 Tsunami Med Tech, LLC Medical instruments and techniques for thermally-mediated therapies
US9433457B2 (en) 2000-12-09 2016-09-06 Tsunami Medtech, Llc Medical instruments and techniques for thermally-mediated therapies
US8758341B2 (en) 2000-12-09 2014-06-24 Tsunami Medtech, Llc Thermotherapy device
US8444636B2 (en) * 2001-12-07 2013-05-21 Tsunami Medtech, Llc Medical instrument and method of use
US9468487B2 (en) 2001-12-07 2016-10-18 Tsunami Medtech, Llc Medical instrument and method of use
US8016823B2 (en) 2003-01-18 2011-09-13 Tsunami Medtech, Llc Medical instrument and method of use
US7892229B2 (en) 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US8313485B2 (en) 2003-01-18 2012-11-20 Tsunami Medtech, Llc Method for performing lung volume reduction
US9113944B2 (en) 2003-01-18 2015-08-25 Tsunami Medtech, Llc Method for performing lung volume reduction
US7344530B2 (en) * 2003-03-26 2008-03-18 Regents Of The University Of Minnesota Thermal surgical procedures and compositions
US20060079869A1 (en) * 2003-03-26 2006-04-13 Bischof John C Thermal surgical procedures and compositions
US20060078538A1 (en) * 2003-03-26 2006-04-13 Bischof John C Thermal surgical procedures and compositions
US7344531B2 (en) * 2003-03-26 2008-03-18 Regents Of The University Of Minnesota Thermal surgical procedures and compositions
US20050080405A1 (en) * 2003-03-26 2005-04-14 Bischof John C. Thermal surgical procedures and compositions
US8846396B2 (en) 2003-07-31 2014-09-30 Universita Degli Studi Di Roma “La Sapienza” Methods for the isolation of cardiac stem cells
US8772030B2 (en) 2003-07-31 2014-07-08 Universita Degli Studi Di Roma “La Sapienza” Cardiac stem cells and methods for isolation of same
US9907599B2 (en) 2003-10-07 2018-03-06 Tsunami Medtech, Llc Medical system and method of use
US8579892B2 (en) 2003-10-07 2013-11-12 Tsunami Medtech, Llc Medical system and method of use
US9050076B2 (en) 2004-11-16 2015-06-09 Uptake Medical Corp. Device and method for lung treatment
US9642668B2 (en) 2004-11-16 2017-05-09 Uptake Medical Technology Inc. Device and method for lung treatment
US20070093818A1 (en) * 2005-08-03 2007-04-26 Lutz Biedermann Bone anchoring device
US8579893B2 (en) 2005-08-03 2013-11-12 Tsunami Medtech, Llc Medical system and method of use
US8696712B2 (en) 2005-08-03 2014-04-15 Biedermann Technologies Gmbh & Co. Kg Bone anchoring device
WO2007084929A3 (en) * 2006-01-18 2007-12-13 Cannuflow Inc Helical extravasation minimization device
US8025648B2 (en) 2006-01-18 2011-09-27 Cannuflow, Inc. Extravasation minimization device
US9113858B2 (en) 2006-11-13 2015-08-25 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US7993323B2 (en) 2006-11-13 2011-08-09 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US20080114297A1 (en) * 2006-11-13 2008-05-15 Uptake Medical Corp. High pressure and high temperature vapor catheters and systems
US8322335B2 (en) 2007-10-22 2012-12-04 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8734380B2 (en) 2007-10-22 2014-05-27 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US8147532B2 (en) 2007-10-22 2012-04-03 Uptake Medical Corp. Determining patient-specific vapor treatment and delivery parameters
US9924992B2 (en) 2008-02-20 2018-03-27 Tsunami Medtech, Llc Medical system and method of use
US8579888B2 (en) 2008-06-17 2013-11-12 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
US8911430B2 (en) 2008-06-17 2014-12-16 Tsunami Medtech, Llc Medical probes for the treatment of blood vessels
WO2010021942A1 (en) * 2008-08-21 2010-02-25 Geno Llc Systems and devices for generating nitric oxide
US8944049B2 (en) 2008-08-21 2015-02-03 Geno Llc Systems and devices for generating nitric oxide
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
US20100043787A1 (en) * 2008-08-21 2010-02-25 Fine David H Systems and devices for generating nitric oxide
US8721632B2 (en) 2008-09-09 2014-05-13 Tsunami Medtech, Llc Methods for delivering energy into a target tissue of a body
US10064697B2 (en) 2008-10-06 2018-09-04 Santa Anna Tech Llc Vapor based ablation system for treating various indications
US9561066B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9700365B2 (en) 2008-10-06 2017-07-11 Santa Anna Tech Llc Method and apparatus for the ablation of gastrointestinal tissue
US9561067B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
US9561068B2 (en) 2008-10-06 2017-02-07 Virender K. Sharma Method and apparatus for tissue ablation
EP2210633A3 (en) * 2009-01-21 2011-06-08 Palo Alto Research Center Incorporated Drug delivery device with sensor system
US20100185143A1 (en) * 2009-01-21 2010-07-22 Palo Alto Research Center Incorporated Sensor system for drug delivery device, drug delivery device having the same and method of using the same
US9480795B2 (en) 2009-01-21 2016-11-01 Palo Alto Research Center Incorporated Sensor system for drug delivery device, drug delivery device having the same and method of using the same
US20100204678A1 (en) * 2009-02-12 2010-08-12 Mir Imran Skin penetrating device and method for subcutaneous solid drug delivery
WO2010093834A2 (en) * 2009-02-12 2010-08-19 Incube Labs, Llc Skin penetrating device and method for subcutaneous solid drug delivery
WO2010093834A3 (en) * 2009-02-12 2010-12-09 Incube Labs, Llc Skin penetrating device and method for subcutaneous solid drug delivery
US8353863B2 (en) 2009-02-12 2013-01-15 InCube Labs, Inc. Skin penetrating device and method for subcutaneous solid drug delivery
US8900223B2 (en) 2009-11-06 2014-12-02 Tsunami Medtech, Llc Tissue ablation systems and methods of use
US9161801B2 (en) 2009-12-30 2015-10-20 Tsunami Medtech, Llc Medical system and method of use
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US10238446B2 (en) 2010-11-09 2019-03-26 Aegea Medical Inc. Positioning method and apparatus for delivering vapor to the uterus
AU2012340751B2 (en) * 2011-11-21 2017-06-01 Incube Labs, Llc Myocardial drug delivery apparatus and methods
US20130218124A1 (en) * 2011-11-21 2013-08-22 Incube Labs, Llc Myocardial drug delivery apparatus and method
US9107993B2 (en) * 2011-11-21 2015-08-18 Incube Labs, Llc Myocardial drug delivery apparatus and method
EP3195897A1 (en) * 2011-11-21 2017-07-26 Incube Labs, LLC Myocardial drug delivery apparatus
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US20150224281A1 (en) * 2012-09-11 2015-08-13 Native Cardiovascular Llc Device and methods for targeted tissue drug delivery
US10118014B2 (en) * 2012-09-11 2018-11-06 Native Cardio, Inc. Device and methods for targeted tissue drug delivery
US9943353B2 (en) 2013-03-15 2018-04-17 Tsunami Medtech, Llc Medical system and method of use
US9782211B2 (en) 2013-10-01 2017-10-10 Uptake Medical Technology Inc. Preferential volume reduction of diseased segments of a heterogeneous lobe
US10299856B2 (en) 2014-05-22 2019-05-28 Aegea Medical Inc. Systems and methods for performing endometrial ablation
US10179019B2 (en) 2014-05-22 2019-01-15 Aegea Medical Inc. Integrity testing method and apparatus for delivering vapor to the uterus
USD845467S1 (en) 2017-09-17 2019-04-09 Uptake Medical Technology Inc. Hand-piece for medical ablation catheter

Also Published As

Publication number Publication date
US7104988B2 (en) 2006-09-12
US6086582A (en) 2000-07-11
US6358247B1 (en) 2002-03-19
US20020156383A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
US6053911A (en) Transvascular TMR device and method
CA2656341C (en) Percutaneous intravascular access to cardiac tissue
US7794444B2 (en) Catheter system and methods for delivery of therapeutic cells to cardiac tissue
CN104254366B (en) Neuromodulation devices, systems and methods for
US5269326A (en) Method for transvenously accessing the pericardial space via the right auricle for medical procedures
US7211041B2 (en) Apparatus and method for delivering therapeutic and diagnostic agents
US9649495B2 (en) Method and apparatus for pacing during revascularization
US6006139A (en) Single pass medical electrical lead with cap electrodes
EP2010263B1 (en) Microcatheter devices and methods for targeted substance delivery
US5938659A (en) Catheter system having cooled multiple-needle electrode and methods thereof
AU712738B2 (en) Steerable catheter
AU2001240107B2 (en) Methods and kits for locally administering an active agent to an interstitial space of a host
US6613062B1 (en) Method and apparatus for providing intra-pericardial access
US5476502A (en) Defibrillator and demand pacer catheters and methods for using same
AU730720B2 (en) Transvascular TMR device and method
US5968010A (en) Method for transvenously accessing the pericardial space via the right atrium
JP4846166B2 (en) Implant delivery catheter system
US5755766A (en) Open-ended intravenous cardiac lead
US6666844B1 (en) Method and apparatus for accessing the pericardial space
US20030216693A1 (en) Tortuous path injection device and method
US20060253183A1 (en) Intramural needle-tipped surgical device
US6554794B1 (en) Non-deforming deflectable multi-lumen catheter
US7400931B2 (en) Devices and methods to stimulate therapeutic angiogenesis for ischemia and heart failure
US9968611B2 (en) Methods and devices for renal nerve blocking
US20180193600A1 (en) Steering engagement catheter devices, systems, and methods

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIOCARDIA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALTMAN, PETER A.;ALTMAN, JOHN D.;REEL/FRAME:039237/0789

Effective date: 20020822